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Abstract 
Tissue hypoxia, or oxygen deficiency in tissue, is usually the result of a locally restricted 
oxygen supply or an abnormal increase in oxygen consumption, or both. Hypoxia is related to 
a variety of pathological conditions including cancer, stroke and ischemic heart disease. In 
locally advanced solid tumors, hypoxic and anoxic regions are often distributed 
heterogeneously due to structurally and functionally abnormal vasculature. Tumor hypoxia 
has been closely associated with poor cancer prognosis after radiation and chemotherapy, and 
is known to encourage tumor proliferation factors, such as growth, apoptosis, angiogenesis 
and metastasis. 
In radiotherapy, dosage (i.e., the amount of radiation required to kill a tumorous tissue) is 
determined by the intrinsic radiosensitivity of the cancer cell population and the tumor 
microenvironment, in particular the oxygen level of the tissue. Therefore, hypoxic tissues are 
known to be resistant to the lethal effects of radiation. The ability to accurately identify the 
hypoxic levels of tumors, and regions within a tumor, can allow clinicians to alter 
radiotherapy treatment planning to improve treatment outcomes. Consequently, considerable 
efforts have been made to identify hypoxia within tumors. 
Of particularly interest at present is to develop chemicals, incorporating hypoxia-
targeting vectors, which specifically accumulate in hypoxic tissue when injected and can then 
be traced/imaged by an imaging modality, thus allowing delineation of hypoxic parts of a 
tumor. The potential of these compounds as markers for hypoxic tumors has long been 
realised, and have been extensively exploited in positron-emission tomography imaging, but 
less so in magnetic resonance imaging. However, developing such compounds for MRI first 
requires determining which of the several available hypoxia-targeting vectors is most 
favourable. As these targeting vectors bind to macromolecular structures, a suitable model for 
such determinations is to probe the binding interactions of these vectors in albumin. Probing 
such interactions has been studied by nuclear magnetic resonance spectroscopy due to its 
general applicability and non-invasive nature. NMR diffusion measurements allow binding 
ligands to be easily differentiated from non-binding molecules by significant differences in 
the diffusion coefficients. The mathematical framework for analysing such data is provided 
by the Kärger equations.  
To understand limits of these equations, such as the short gradient pulse 
approximation, and thus the conditions under which these equations are valid, a detailed 
derivation of these equations for the case of two freely diffusing exchanging species is 
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presented along with the simplifications that result in the slow and fast exchange limits. This 
leads to the population weighted diffusion equation, which is then used to quantitatively 
characterise the binding properties of the hypoxia-targeting vectors in albumin by the number 
of binding sites, n and the association constant, K. 
 The binding properties of three hypoxia-targeting vectors were investigated: 2-
nitroimidazole, 4-nitroimidazole and 6-nitroquinoline, using NMR diffusion and relaxation 
measurements. For the vectors which showed binding in diffusion NMR experiments, the 
binding was probed at three different protein concentrations (0.23, 0.30 and 0.38 mM) with 
drug concentrations ranging from 0.005–0.16 M at 298 K. Simultaneously fitting the Kärger 
model to the data obtained from the NMR measurements (D, R1 and R2) yielded significantly 
more robust results than individually fitting each dataset, from which n and K were 
determined to be 21 ± 3 and 53 ± 4 M−1, respectively. However, n and K were not 
determined for 4-nitroimidazole and 6-nitroquinoline as any binding interactions were not 
detected by the diffusion data. However, it is most likely the binding interactions are 
considerably weak based on the relaxation data, and thus the associated extremely fast 
exchange process was outside the time scale of the diffusion measurements.   
 With 2-nitroimidazole possessing the strongest binding interactions of the three 
vectors studied, 2-nitroimidazole was conjugated to a saturated lipid chain, thus synthesising 
1-(2-nitroimidazoyl)octadecane to be used as an active hypoxia-targeting amphiphilic vector. 
Hypoxia-specific paramagnetic liposomes were then formulated by incorporating 
commercially available paramagnetic amphiphilic chelates, and 1-(2-
nitroimidazoyl)octadecane lipids within the bilayer membranes of the 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine lipids. Two sets of hypoxia-specific paramagnetic liposomes were 
formulated: one containing PEGylated lipids and one without, to improve circulation times 
and optimise targeting, respectively. However, it is likely the absence of PEGylated lipids 
resulted in less stable liposomes. The relaxivity of the hypoxia-specific paramagnetic 
liposomes relative to the commercially available contrast agent, Magnevist, increased by a 
range of approximately 83 - 162%.       
The hypoxia-targeting ability of the liposomes was then assessed by comparing the 
cellular uptake of targeted and non-targeted paramagnetic liposomes in two cell lines: SH-
SY5Y human neuroblastoma and MCF-7 human breast cancer, in normoxic and hypoxic 
conditions. Inductively coupled plasma mass spectrometry revealed a three and five-fold 
increase in the gadolinium concentration of the hypoxic cells relative to the normoxic cells in 
the SH-SY5Y and MCF-7 cell lines, respectively, confirming the hypoxia-targeting ability of 
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these liposomal formulations. However, indistinct contrast difference was observed between 
the MR images of the normoxic and hypoxic cells in either cell-line, thus suggesting the need 
to design liposomal formulations with either higher gadolinium content, or better contrast 
enhancement efficiency, or both. Nevertheless, the primary aim of confirming the hypoxia-
specificity of the synthesised paramagnetic liposomes was achieved. This now presents an 
opportunity to develop hypoxia-specific theranostic liposomes by incorporating hypoxia-
activated prodrugs in addition to the targeting and contrast components incorporated in this 
thesis, thereby combining diagnostic and therapeutic capabilities in a single agent. 
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Chapter 1. Introduction 
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 Cancer 1.1
The existence of cancer has been known since ancient times [1]. Since the 1900s, numerous 
cancer research programs have contributed to an explosion of knowledge in oncology in such 
areas as the etiology, pathophysiology, detection and treatment of cancer [2]. However, to 
this day, cancer continues to have a significant impact on world health. In particular, cancer-
related statistics reveal the true prevalence of this disease. In Australia, an estimated 138,000 
new cases were diagnosed in 2018, with an estimated 49,000 deaths, whereas in the United 
States, an estimated 1,735,000 new cases were diagnosed, with 610,000 people dying from 
the disease [3, 4].       
Cancer is a disease caused by abnormal cell function and division. Normal cell 
function and reproduction is based on a controlled ‘supply and demand’ system [5], where 
cells will only be sent a signal to reproduce if there are cells that need to be replaced. Cells 
may need to be replaced due to old age, trauma or mutations preventing the cells from 
functioning properly. Once these damaged cells are replaced, the cells leave the ‘active’ 
reproductive phases, and remain ‘inactive’ until another signal is received. Some cells lose 
this control during cell division and begin to divide erratically. This creates an imbalance in 
cell numbers, and thereby results in the formation of a tumor mass [6]. However, not all 
tumors are cancerous. Non-cancerous tumors are referred to as benign, whilst cancerous 
tumors are referred to as malignant [1]. Benign tumors will not invade nearby tissues or 
spread to other parts of the body. Such examples include fibroids in the uterus and lipomas 
[7, 8]. Malignant tumors on the other hand, can invade nearby tissues and spread to other 
parts of the body via the bloodstream, lymphatic vessels or locally, through a process called 
metastasis [1]. 
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Figure 1: A schematic representation of a) normal cells, b) abnormal cells (i.e., a benign tumor) and c) 
cancerous cells (i.e., a malignant tumor) within a tubular structure.  
 
At present, many different types of cancer treatments are available (e.g., surgery, 
chemotherapy, hormonal therapy, radiation therapy and immunotherapy [1]). Depending on 
the type of cancer and how advanced it is, some patients may only have one type of 
treatment, while others may have a combination of treatments. Chemotherapy and 
radiotherapy are two commonly used, highly effective cancer treatment options, and are 
briefly discussed below. 
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 Chemotherapy 1.1.1
Chemotherapy uses cytotoxic drugs to kill tumor cells by interfering with cell replication 
through a variety of mechanisms [9]. These mechanisms include breaking the DNA strands 
(e.g., Cyclophophamide), cross-links in the DNA preventing replication of the cells (e.g., 
Cisplatin) or inhibition of DNA synthesis and function (e.g., Mitomycin C) [6]. One of the 
limitations of cytotoxic chemotherapy is that it is not able to distinguish between normal and 
malignant cells. As a result, normal cells are also killed during treatment, resulting in side 
effects such as neutropenia, nausea, vomiting, stomatitis and alopecia [6].      
 Radiotherapy 1.1.2
Radiotherapy uses high energy X-rays, electrons or protons to kill cancer cells [6, 10]. The 
basic principle of radiotherapy is that such ionizing radiation carries enough energy to cause 
atoms to gain or lose electrons by forcing electrons to leave their orbitals around the nucleus. 
This results in DNA damage and other cellular changes, thus causing cell death [11].    
Initial forms of radiotherapy treatment involved the use of radioactive sources, but 
with technological advances such as the development of the linear accelerators (linacs), a 
variety of radiation types can now be generated in a much more controlled manner. Recent 
developments have seen linear accelerators combined with other modalities such as magnetic 
resonance imaging (MRI) scanners, as is the case with the Australian MRI-Linac program 
[12]. Such developments allow for real time imaging and treatment, which allows for greater 
radiotherapy treatment accuracy and reduced damage to surrounding healthy tissue.   
 Tissue Hypoxia 1.2
Whilst new chemotherapeutic drugs with novel action mechanisms may lead to more 
effective anticancer drugs [13] and advancements in radiotherapy may improve the accuracy 
of the radiotherapy dose delivered [12], the effect of both treatment modalities on normal and 
malignant cells are governed by biological factors. One of these factors is tissue oxygenation. 
The role of oxygen (O2) as the terminal electron acceptor in oxidative phosphorylation 
makes it an essential nutrient for mammalian cells, to such an extent that intricate control 
mechanisms have evolved to maintain a sufficient supply for the mitochondria. These 
mechanisms control factors such as blood flow, blood vessel dilation and O2 extraction 
fraction to maintain a life-sustaining level of O2. However, the deprivation of sufficient O2 
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required to maintain oxidative phosphorylation in cells results in a phenomenon called tissue 
hypoxia. 
 For most solid tumors, hypoxia (i.e., tumor hypoxia) develops due to an inability of 
the vascular system to supply adequate amounts of O2 to the growing tumor mass. More 
specifically, this is due to structural and functional abnormalities of tumor microvessels [14], 
increased diffusion distances between blood vessels of the expanding tumor cell mass, and a 
reduction in O2 in the blood due to disease or treatment related anaemia [15]. Hence, there are 
three distinct types of tumor hypoxia [16]: perfusion related hypoxia (inadequate blood flow 
due to structural and functional abnormalities), diffusion related hypoxia (increased O2 
diffusion distances), and anaemic hypoxia (reduced O2 carrying capabilities of the blood).    
 Hypoxia can be quantified using partial pressure of O2 measurements (pO2). Such 
measurements reflect the amount of dissolved O2 present in the blood. In normal tissues, the 
median pO2 values range between 24 and 66 mm Hg, whereas values less than 20 mm Hg are 
common for malignancies [17]. A typical example reveals the median pO2 of normal cervical 
mucosa to be 36 mm Hg [17], whereas in cancerous tissue, the value drops from 20 mm Hg at 
stage zero to 5 mm Hg at stage two [18, 19].   
Based on a large body of clinical evidence, the hypoxia-mediated aggressive 
behaviour of cancer cells and their resistance to therapy is suggested to be orchestrated by the 
hetero-dimeric transcription factor, hypoxia inducible factor-1 alpha (HIF-1α) [20, 21]. HIF-1 
controls the expression of a variety of genes, from which any changes to the proteome and 
genome of neoplastic cells result in the emergence of more aggressive clones able to 
overcome nutrient deprivation and hostile environments [15]. This ability of hypoxic cells to 
overcome hostile environments impairs the effectiveness of radiotherapy and other such 
treatments. The effectiveness of these treatments become progressively limited with 
decreasing O2 concentration, to such an extent that approximately 3-4 times more dose is 
required to be administered under hypoxic conditions compared to well-oxygenated 
conditions to achieve the same biological effect (i.e., cell death) [15]. Due to the inability to 
detect hypoxic regions, the increased dose (e.g., radiation) required for the treatment of 
hypoxic tumors/regions is not accounted for during treatment planning, thus resulting in 
treatment failures. As a result, several methods have been established to detect tumor hypoxia 
[22, 23]. These can be classified as invasive or non-invasive detection methods, and are 
discussed below. 
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 Measuring Tumor Hypoxia 1.3
 Invasive Methods 1.3.1
O2-sensitive electrodes have been used to measure pO2 in vivo [24-27]. O2 electrodes are 
necessarily invasive. The direct correlation of the signal of the electrode and the measured 
pO2 value causes the O2 electrode to be inaccurate in hypoxic applications [28]. This 
limitation has been overcome with the development of fluorescent needle probes, where the 
signal increases with decreasing O2 due to quenching of the optical signal [28-30]. Whilst 
such needle probes have proven to be more successful, fluorescent needle probes are still 
limited by tumor accessibility due to its invasive nature. As a result, this thesis will look to 
utilise non-invasive methods, which are not limited by tumor accessibility.   
 Non-Invasive Methods 1.3.2
Current non-invasive methods for assessing tumor hypoxia include fluorescence optical 
imaging [23], positron emission tomography (PET) or single photon emission computed 
tomography (SPECT) detection of radiolabelled tracers [31-33], and MRI techniques (e.g., 
Blood Oxygen Level Dependent (BOLD)) [34, 35]. Whilst optical imaging offers advantages 
such as high sensitivity, a large number of hypoxia-sensitive agents and low cost, one major 
challenge is the limited penetration depth of both excitation and emission light in living 
organisms [23]. PET, SPECT and MRI methods do not present such limitations in vivo and 
are beneficial in the clinic to obtain serial images which observe growth-dependent changes, 
three-dimensional radiotherapy treatment plan distributions and evaluations of therapeutic 
response. As these methods need to be sensitive to pO2 levels relevant to tumor therapy, the 
challenge for hypoxia imaging is to measure low levels of tissue pO2 on a spatial scale [15]. 
SPECT is advantageous in that isotopes such as Technetium-99 are readily available at low 
cost with a convenient half-life for hypoxic measurements while 
18
F PET offers superior 
spatial resolution and more accurate quantitation [36]. However, both these techniques 
expose patients to harmful effects of ionizing radiation. Hence, MRI is the non-invasive 
method of choice as it does not deal with ionizing radiation, and will be the imaging modality 
used in this thesis.  
In MRI, currently of significant interest in tumor hypoxia detection and monitoring is 
BOLD MRI [35]. It is particularly appropriate for examining oxygenation responses to 
external interventions, as it facilitates rapid interrogation of vascular oxygenation [37-40]. 
Due to its sensitivity to changes in blood flow and deoxyhaemoglobin (deoxy-Hb) content 
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[41], BOLD imaging distinguishes (paramagnetic) deoxy-Hb from (diamagnetic) 
oxyhaemoglobin (O2Hb) allowing vascular oxygenation changes to be revealed through 
appropriately parameterised-weighted imaging. BOLD-MRI is advantageous in that repeated 
high temporal and high spatial resolution images can be obtained without the administration 
of an external contrast agent. However, the progression of this method is limited due to the 
inability of BOLD MRI to measure tissue pO2 directly [15]. Such limitations have created 
interest in hypoxia-targeting vectors, which could potentially aid in the development of 
methods capable of measuring pO2 directly. These hypoxia-targeting vectors are discussed 
below.  
 Hypoxia-Targeting Vectors 1.4
Hypoxia-targeting vectors are molecules, which possess hypoxia sensitive properties. Such 
vectors include nitroimidazoles, quinones, aromatic and aliphatic N-oxides, and metal 
complexes, which all undergo activation in hypoxic conditions, irreversibly causing change 
to their intrinsic properties. With the exception of nitroimidazoles, these compounds are yet 
to be used in tumor imaging, but have been used experimentally as hypoxia activated 
prodrugs (HAPs) for cancer treatment [42-47]. Nitro (-NO2) groups undergo selective 
enzyme-mediated reduction in low O2 conditions, which is a favourable property to be 
exploited in molecular targeting of hypoxia. Furthermore, as nitro-based compounds, such as 
nitroimidazoles, have been studied extensively as hypoxia-targeting vectors and used in 
different imaging modalities [48, 49], these types of compounds will remain the focus of this 
thesis. 
Nitroimidazoles have been studied for the purpose of exploiting hypoxia selective 
properties since the 1970s [48] after these molecules were found to selectively bind to the 
macromolecules of hypoxic regions. Intracellular reduction of nitroimidazoles occur in all 
cells, however, with inadequate O2 supplies, further reduction leads to reactive products 
capable of binding to cellular components [50]. These products are formed following an 
enzyme-mediated single-electron reduction of the nitro group to a free radical. Even though 
the reduction pathway may proceed in successive steps past the hydroxylamine derivative, it 
ultimately terminates at the relatively inactive amine derivative [49], as shown in Figure 2. 
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Figure 2: Cellular reduction pathway for nitroimidazoles, which terminates at the amine derivative. 
 
 As the compound enters the cell by diffusion through the membrane, its lipophilicity 
predominately determines the depth of the intracellular interaction. In anaerobic organisms, 
the pyruvate:ferredoxin oxidoreductase complex is responsible for the initial single-electron 
reduction. In mammalian cells, a specific enzyme responsible for this reduction has not yet 
been identified, however numerous enzymes are capable of reducing nitroimidazoles [49, 51].  
 The higher electron affinity of the intracellular O2 in comparison to the nitro group 
causes a reversal of the initial reduction to the free radical anion. The intracellular O2 
concentration determines the rate of oxidation, hence the O2 sensitivity of the reaction is 
provided in the initial step of the reaction pathway [49]. Subsequent steps provide the 
retention required to differentiate between hypoxic and normoxic tissue. Retention occurs in 
tissues with low O2 concentrations, as the rate of reoxidation of the original compound is low, 
allowing further reductive reactions to occur.    
The most widely used nitroimidazole-based hypoxia-targeting vectors are 2-, 4- and 
5-nitroimidazole (Figure 3). The exact mechanism of nitroimidazoles binding with 
macromolecules in hypoxic cells is largely unknown [52]. Similar to the macromolecular 
binding of nitrofurans in bacteria [53] and rat microsomes [54], and nitrothiazoles in 
schistosomes [55], it is speculated the majority of macromolecular binding of nitroimidazoles 
also occurs to cellular proteins. Previous studies [53, 56] have shown the biochemical 
reduction of nitro groups in aromatic nitro compounds to arylamines via nitroso and 
hydroxylamino derivatives following enzymatic activation by enzymes such as xanthine 
oxidase, NADPH cytochrome P450 reductase and NADPH cytochrome c reductase [57, 58]. 
With a variety of hydroxylamines known to bind to cellular macromolecules [59], it is 
believed these may also be responsible for the macromolecular binding of nitroimidazoles 
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[60]. Studies involving misonidazole, a nitroimidazole derivative, detected radioactivity in 
DNA, RNA and protein fractions after administration of [
14
C]misonidazole, and a molecule 
with a mass-to-charge ratio corresponding to the hydroxylamine derivative of misonidazole 
following chemical reduction [60]. This further indicates that the hydroxylamine derivative is 
likely to be responsible for the binding of nitroimidazoles to cellular macromolecules. 
 
 
Figure 3: Molecular structures of a) 2-nitroimidazole, b) 4-nitroimidazole and c) 5-nitroimidazole. 
 
 With the speculation of the above mentioned hypoxia-targeting vectors binding to 
cellular proteins, its presents an opportunity to characterise the binding of these molecules 
with plasma proteins (e.g., serum albumin), which is a common practice in the early stages of 
drug development. Such interactions can be probed using nuclear magnetic resonance (NMR) 
methods, and then quantitatively characterised using mathematical models such as the Kärger 
equations. These ideas will be discussed in greater detail later in this thesis and will be used 
to characterise the binding interactions of different hypoxia-targeting vectors. 
 Hypoxia-Targeting Vectors in MRI 1.4.1
The availability of hypoxia-targeting vectors such as those discussed above, has led to the 
development of several imaging probes targeting tissue hypoxia, of which the most 
prominent are 
18
F labelled fluoromisonidazole (
18
F-FMISO) [61] for PET imaging and 
99m
Technetium labelled propylene amineoxime [62] for SPECT imaging. Furthermore, 
several multifluorinated derivatives comprising hypoxia-targeting vectors have been 
synthesised to assess tumor hypoxia by 
19
F NMR spectroscopy. However, only one such 
derivative, gadolinium tetraazacyclododecanetetraacetic acid monoamide conjugate of 2-
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nitroimidazole (GdDO3NI) (Figure 4) [63, 64], has been reported for 
1
H MRI. As a result, 
this thesis will look to expand on this area of research. 
 As will be discussed later, the signal intensity in 
1
H MRI is related to the relaxation 
rate of in vivo water protons, which can be enhanced using a contrast agent administered prior 
to scanning. These agents utilise paramagnetic metal ions and are evaluated on their ability to 
increase the relaxation rate of nearby water protons relative to their concentration (i.e., 
relaxivity). Gadolinium (Gd) (i.e., Gd(III)) is the most widely used metal centre for such 
proton relaxation agents [65, 66]. While contrast agents such as GdDO3NI provide sufficient 
contrast with confirmed targeting capabilities, both these properties can be enhanced by 
encapsulating the ‘contrast’ and ‘targeting’ components within supramolecular structures. 
Such structures present higher relaxivities, and afford relatively easy attainment of favourable 
pharmacological characteristics, making them excellent candidates as possible carriers for 
targeted MRI contrast agents, and potentially the next generation of hypoxia-specific 
theranostic agents. 
 
 
Figure 4: Molecular structure of Gadolinium tetraazacyclododecanetetraacetic acid monoamide 
conjugate of 2-nitroimidazole (GdDO3NI), with the contrast and targeting components labelled. 
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 Aims and Objectives 1.5
With the ultimate aims of investigating the binding properties of different hypoxia-targeting 
vectors, and then synthesising a hypoxia-specific paramagnetic agent using one of the studied 
vectors, the following objectives were set in this project:  
(i) understand and derive the two-site binding Kärger model,  
(ii) quantitatively characterise the binding of different hypoxia-targeting vectors 
using NMR methods,  
(iii) design, synthesise and characterise hypoxia-specific paramagnetic 
supramolecular nanoparticles/agents, which incorporate paramagnetic MRI 
contrast agent and active hypoxia-targeting vectors, and  
(iv) investigate the hypoxia-targeting ability of the synthesised structures/agents in 
vitro by assessing the retention of paramagnetic metal ions in cells under 
hypoxic and normoxic conditions. 
In this thesis, Chapters 2 – 4 present the underlying theory and concepts required to 
understand experimental work of this project. In Chapters 2 and 3, the basic principles of 
NMR and MRI are detailed, respectively. This becomes relevant in the vector binding and in 
vitro cell studies later in this thesis. With the aim of developing a more effective 
paramagnetic agent than that currently reported in literature, the different types of contrast 
agents are reviewed in Chapter 4, ultimately leading to the structure of choice for this project. 
Experimental/original work is presented from this point forward, starting with a complete 
derivation of the two-site binding Kärger model, with considerations of both the slow and fast 
exchange limits, presented in Chapter 5. Using this model for quantitative analysis, the 
binding studies of different hypoxia specific vectors are presented in Chapter 6. The 
development of the hypoxia specific paramagnetic agents is detailed in Chapter 7, along with 
the characterisation of their efficiency as MRI contrast agents. The hypoxia-targeting abilities 
of the newly synthesised agents in vitro cell studies are reported in Chapter 8. To conclude, 
future research directions are presented with preliminary results in Chapter 9.  
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Chapter 2. Nuclear Magnetic Resonance, 
Relaxation & Diffusion 
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The first step in using NMR methods to determine suitable hypoxia-targeting vectors is to 
understand the basic concepts of the chosen method. This chapter presents the fundamental 
aspects of NMR, looking at the basic notions of magnetisation, precession, excitation, 
acquisition, relaxation and diffusion.  
  Overview of NMR 2.1
All atomic nuclei possess four important properties: mass, electric charge, magnetism and 
spin. Whilst mass and electric charge are responsible for the physical and chemical properties 
of matter, magnetism and spin form the basis of NMR. Magnetism is what enables the atomic 
nuclei to act as a small bar magnet when placed in an external magnetic field. Spin, an 
intrinsic quantum mechanical property, is much more difficult to visualise. Simplistically, it 
can be described as the magnetic moment of an atomic nucleus spinning about its own axis, 
which is associated with an inherent angular momentum referred to as spin angular 
momentum (Figure 5). Spin is characterised by a quantum number, I. As spins with I = ½, 
such as the 
1
H nuclei
 
were studied in this thesis, all discussions in this thesis will relate to 
spin-half nuclei.   
 
 
Figure 5: A simplified schematic representation of nuclear spin. 
 
The effect of NMR exists due to nuclear spin, and its interaction with an external 
magnetic field, B0 [67]. The interaction of the nuclear spin and B0 results in a simultaneous 
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rotating revolving motion of the spins referred to as precession. The angular frequency of 
precession is referred to as the Larmor frequency, ω0,  
 0 0 ,B     (2.1) 
where γ is the gyromagnetic ratio of the nucleus and B0 is the applied magnetic field strength. 
As a nuclear spin is precessing, it will attempt to align its magnetic moment with B0 to 
minimise the energy of the magnetic interaction between the spin and B0. The difference in 
energy of the magnetic interaction of a proton when aligned and anti-aligned with B0 can be 
calculated to be 4.23 × 10
-26 J at a magnetic field strength of 1.5 T. However, in comparison, 
the thermal energy associated with a proton at 37  ̊C is approximately 105 times larger (≈10-21 
J). This implies that the effect on the spins due to the interaction of the spin and the magnetic 
field is likely to be almost insignificant. Hence, each spin will mostly remain randomly 
orientated with only a small preference towards the direction of the applied field. However, 
as even the smallest of samples contain an extraordinary number of nuclei, this small 
alignment, when summed over the entire sample, can conduce to a net magnetisation, M 
(Figure 6), with a thermal equilibrium magnitude, M0. The evolution of M is described 
mathematically via the Bloch equations and will be presented in Chapter 5.  
   
 
Figure 6: A schematic representation of nuclear spins a) before and b) after the application of an external 
static magnetic field, B0. The magnetic moments of the nuclear spins are randomly oriented in the 
absence of B0, resulting in a trivial net magnetisation due to the Earth’s magnetic field, while in the 
presence of B0, the magnetic moments tend to align with B0 resulting in a net magnetisation, M.  
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It is necessary to be able to detect the net magnetisation to extract information from 
the sample. As only the transverse component of the net magnetisation is detectable (i.e., the 
component orientated perpendicular to B0), an NMR experiment begins by nutating M away 
from B0 using a perpendicular magnetic field, B1, oscillating at the Larmor frequency for a 
short period of time. This short burst of an oscillating perpendicular magnetic field can be 
achieved by a radio-frequency (rf) pulse. The resonance between the rf pulse and the Larmor 
frequency of the nuclei results in a continuous push of the net magnetisation towards the 
transverse plane, resulting in a transverse magnetisation magnitude, Mxy. In NMR, it is 
common to name the rf pulse based on the angle by which the net magnetisation is rotated 
(e.g., 90 or 180° pulses, or equivalently /2 and  pulses, as shown in Figure 7).     
 
 
Figure 7: The effect of two common rf pulses on the net spin magnetisation at thermal equilibrium: a) 90° 
pulse maximising the magnetisation component in the x,y-plane, where the NMR signal is detected. b) 
180° pulse inverting the spin-populations. 
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During the application of an rf pulse, two precessions are involved: one about B0 and 
one about B1. In the laboratory frame of reference, two simultaneous precessions make the 
overall motion of the net magnetisation appear as a spiral. In such situations, this can be 
visualised more simply by considering a frame of reference rotating at the Larmor frequency. 
In a rotating frame of reference, the spins precessing about B0 will appear stationary. The 
rotating frame of reference accounts for the effects of B0, thus B0 can be ignored. 
Furthermore, in the rotating frame, the rf pulse will appear to be static and the net 
magnetisation will appear to only precess about B1, thus simplifying the initial two 
precessions to one.  
After the rf pulse is turned off, the net magnetisation, which is now in the transverse 
plane, continues its usual precession about B0. A changing magnetic field is generated by this 
precessing magnetisation, which induces an oscillating electric current via Faraday induction 
in a nearby receiver coil of the NMR spectrometer. This induced current is then digitised to 
form the NMR signal commonly referred to as the free induction decay (FID). As it is 
difficult to deduce the Larmor frequencies of nuclei in different environments from the FID, 
the FID is Fourier transformed to the frequency domain [68]. The essence of Fourier 
transform involves multiplying the FID by trial cosine waves to pick out the intensity of the 
corresponding frequency. This mathematical process results in the conversion of the 
exponentially decaying signal to a Lorentzian-shaped peak (Figure 8). This forms the NMR 
spectrum, where the Larmor frequencies can be easily identified by the corresponding peak 
[68, 69].    
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Figure 8: A simulated free induction decay (left) Fourier transformed to obtain the NMR spectra (right). 
The offset Larmor frequency was set to 50 Hz.  
 
 Relaxation 2.2
During the acquisition of an FID, the magnetisation returns to equilibrium by a process 
known as spin relaxation. There are two primary forms of relaxation; spin-lattice relaxation 
(returning of the longitudinal magnetisation to its equilibrium value) and spin-spin relaxation 
(reduction of the transverse magnetisation to zero). The time required for spin-lattice 
relaxation and spin-spin relaxation to occur is denoted by the decay constants T1 and T2, 
respectively, which observes the rotational motion of molecules and can be used to probe the 
molecular dynamics of solutions. The two relaxation processes are outlined in Figure 9. 
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Figure 9: A schematic representation of the relaxation processes: a) spin-lattice relaxation and b) spin-
spin relaxation. Spin-lattice relaxation is the return of the longitudinal magnetisation (depicted by the 
sum of the vertical components of the red arrows in (a)) to its equilibrium value along the z-axis, while 
spin-spin relaxation is the reduction of the transverse magnetisation (depicted by the dephasing of the red 
arrows in (b)) to zero in the xy-plane (from left to right).  
  
  Spin-Lattice Relaxation 2.2.1
The spin-lattice relaxation time, T1, quantifies the rate at which energy is transferred from the 
nuclear spin system to the neighboring molecules (i.e., the lattice). This is relaxation in the z-
direction. On the microscopic scale, spin-lattice relaxation refers to the movement of spin 
populations back to their Boltzmann distribution values [70]. The return of the magnetisation 
in the z-component, Mz, to its equilibrium value, M0, can be described by the first-order 
process [70, 71] 
 0
1
( )
.zz
M MdM
dt T

    (2.2) 
After a period of time equivalent to T1, Mz returns to 63% of its equilibrium value. 
Experimentally, it is therefore common practice to set a delay of 13 5 T   to ensure MZ has 
almost returned to 100% of its equilibrium value.  
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  Spin-Spin Relaxation 2.2.2
Spin-spin relaxation corresponds to the loss of transverse magnetisation, resulting from the 
loss of coherences amongst the spins precessing in the x-y plane. The loss of magnetisation in 
the x and y components can be described by the first order processes [70, 71]  
 
2 2
 and .
y yx x
dM MdM M
dt T dt T
    (2.3) 
Similar to spin-lattice relaxation, the signal decay resulting from spin-spin relaxation is 
described mathematically by an exponential curve. However, T2 differs from T1 in that the 
signal is reduced to 37% of its original value after a time period of T2 (whereas with T1, 63% 
of the signal is recovered after a time period of T1).  
  Pulse Sequences for Studying NMR Relaxation 2.2.3
2.2.3.1 Inversion Recovery Pulse Sequence 
The inversion recovery method is the most commonly used method to measure T1 [72]. The 
inversion recovery pulse sequence consists of a π pulse, followed by a π/2 pulse after a time 
delay of τ, as shown in Figure 10.  
 
 
Figure 10: The inversion recovery pulse sequence. The π pulse inverts the magnetisation from the z to the 
–z axis. During time τ, the magnetisation relaxes back to equilibrium, after which the π/2 pulse is applied 
to rotate the magnetisation into the x-y plane for signal detection. The decaying sinusoid at the end of the 
sequence represents the acquired signal, S. 
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A profile of the recovery of the longitudinal magnetisation can be obtained by 
repeating the sequence with different τ delays. The intensity of the observed longitudinal 
magnetisation, Mz is described by [70] 
 10( ) (1 2 ).
T
zM M e



    (2.4) 
Eq. (2.4) can then be regressed onto the longitudinal magnetisation recovery profile to 
determine T1 (Figure 11). 
 
Figure 11: Non-linear regression of Eq. (2.4) to the longitudinal magnetisation recovery profile of 0.03 M 
2-nitroimidazole in D2O (298 K) using 16 values of τ ranging from 0.1 – 70 s to obtain a T1 of (10.60 ± 
0.01) s. 
 
When obtaining a longitudinal magnetisation recovery profile, each repetition of the 
pulse sequence is separated by a recycle delay of 15 T   to ensure that the magnetisation has 
returned to equilibrium. Prior to determining T1, 15 T  can be estimated with the relationship 
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 1 ,
ln(2)
nullT

   (2.5) 
where null  is the time delay at which zero (or minimal positive) signal is obtained. Whether a 
signal is positive or negative is determined by   relative to null . 
2.2.3.2 Carr-Purcell-Meiboom-Gill Pulse Sequence 
The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence is the most commonly used method 
to measure T2. This pulse sequence consists of a π/2 pulse, followed by a series of π pulses, as 
shown in Figure 12.  
 
 
Figure 12: The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence consisting of a π/2 pulse and n 
repetitions of the Hahn spin-echo unit (τ/2-π-τ/2).  
 
The number of echo cycles is varied in an arrayed fashion. The exponential decay 
curve is obtained by plotting the intensities of the echo signals against τ. T2 can be determined 
by regressing     
 
 
2
0( )
T
xyM M e



   (2.6) 
onto the magnetisation decay curve (Figure 13).   
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Figure 13: Non-linear regression of Eq. (2.6) to the transverse magnetisation decay profile of 0.03 M 2-
nitroimidazole in D2O (298 K) using 10 values of τ ranging from 0.03 – 15 s to obtain a T2 of (1.427 ± 
0.005) s. 
 
The CPMG sequence is a modification of the spin-echo pulse sequence first proposed 
in 1950 by Erwin Hahn comprising two /2 pulses with τ/2 delays in between the pulses and 
prior to acquisition [73]. The first /2 pulse excites the net magnetisation to precess in the 
transverse plane. However, due to magnetic field inhomogeneities and different chemical 
shifts in the case of multiple resonances, the magnetisation components begin to precess at 
slightly different rates. Hence, the Hahn spin echo sequence was modified by replacing the 
second /2 pulse with a  pulse [74], which inverts the magnetisation and refocusses the 
components. However, this modified sequence is still prone to diffusion artefacts (i.e., 
different static fields due to self-diffusion). To accommodate for these artefacts, Carr, Purcell, 
Meiboom and Gill shifted the phase of the rf of the /2 pulse by /2 relative to the phase of 
the  pulses [75] and repeated the echo cycle multiple times.  
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 Diffusion 2.3
Diffusion, or more specifically self-diffusion, is a type of translational motion, describing the 
random thermal motion of molecules or small particles at thermal equilibrium (Figure 14) 
[76, 77]. In diffusion, no bulk displacement occurs, which is different from other types of 
motion, such as mechanical displacement of solid bodies or advection in liquids [78]. As 
there is no bulk displacement, diffusion can be assessed by measuring the mean squared 
displacement (MSD) of single diffusing particles. While the mathematical basis of diffusion 
is presented in Chapter 5, for now, it will suffice to know that diffusion is characterised by a 
diffusion coefficient, D (m
2
s
-1
), and can be physically interpreted through the Stokes-
Einstein-Sutherland equation [79-81],  
 
6
kT
D
r
   (2.7) 
where k is the Boltzmann constant, T is the temperature,  is the solvent viscosity, and r is 
the Stokes (or effective hydrodynamic) radius of the diffusing species. Typical diffusion 
coefficients in aqueous solutions range from 10
-11
 (e.g., large protein molecules: albumin) to 
10
-9
 m
2
s
-1
 (e.g., water) [82-84]. Diffusion measurements can be used to probe the molecular 
dynamics of processes ranging from large-scale water management [85] to protein 
interactions [86, 87]. 
 
 
Figure 14: A schematic representation of molecular diffusion, with the arrows depicting the random 
thermal motion of the molecules.  
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 Diffusion NMR Pulse Sequences  2.3.1
The use of magnetic field gradients to measure diffusion coefficients was initiated by Erwin 
Hahn with the discovery of the spin-echo [76]. Spin-echoes originate from a refocusing of the 
spin magnetisation after dephasing due to either spin-spin relaxation or gradient pulses [88]. 
NMR diffusion measurements are mostly commonly obtained using Pulsed Gradient Spin-
Echo (PGSE) or Pulsed Gradient Stimulated Echo (PGSTE) sequences (Figure 15). 
 
Figure 15:  a) A PGSE pulse sequence with π/2 and π rf pulses and magnetic gradient pulses of 
magnitude, g and duration, δ. The timescale of the diffusion measurements is represented by Δ. b) A 
PGSTE pulse sequence, which differs from the PGSE sequence with two π/2 pulses replacing the π pulse, 
forcing the magnetisation onto the z-axis and then onto the x-y plane. In this sequence, the spin 
magnetisation is subject to spin-spin relaxation during the τ delays and spin-lattice relaxation during the 
T delay. S denotes the acquired signal. Typically δ is in the range of 0-10 ms, Δ is in the range of ms to s 
and g ranges from 0 to 20 Tm
-1
 [76, 89]. 
 
In the PGSE sequence, the π/2 rf pulse flips the net spin magnetisation (initially 
oriented along the static magnetic field) into the transverse plane. The first gradient pulse 
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then winds the magnetisation into a helix (Figure 16). This will be discussed further in 
Section 3.1.1. During Δ, translational diffusion will attenuate the radius of the helix. The π rf 
pulse will then change the chirality of the helix. The application of the second gradient pulse 
unwinds the magnetisation, at which point the signal is acquired. The PGSTE sequence is 
similar to the PGSE sequence in the application of the gradient pulses, but differs in the 
application of the rf pulses. Similar to the PGSE, the first π/2 rf pulse of the PGSTE flips the 
spin magnetisation into the transverse plane. The π rf pulse of the PGSE is then replaced by 
two separated π/2 rf pulses. The magnetisation is thus stored longitudinally during the bulk of 
the diffusion time and has a sinusoidal dependence (in contrast to the helical magnetisation 
arising during the PGSE sequence). The third π/2 rf pulse flips the magnetisation back into 
the transverse plane, but in the opposite direction to the first π/2 rf pulse. The signal is then 
acquired. It is important to note that the two extra π/2 pulses in the PGSTE sequence have the 
same combined effect as the π pulse with regard to gradients winding and unwinding the 
magnetisation helix. However the PGSTE is advantageous in that it caters for systems with a 
large T1 relative to their T2 (i.e., T1 >> T2) [89].  
 
 
Figure 16: Schematic representation of the formation of a magnetisation helix following the application of 
a gradient pulse. Prior to the application of any pulses, the net magnetisation is initially oriented in the 
direction of the static magnetic field (i.e., B0). The application of the rf pulse flips the net magnetisation 
into the transverse plane (left), after which the application of a gradient pulse winds the magnetisation 
vectors into a helix.  
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Experimentally, a series of measurements can be performed with different magnetic 
field gradients, g. This results in different amplitudes of the acquired signal, which can be 
described by the modified Stejskal-Tanner expression [76, 90], 
  
2
0 exp ,
3
S M g D


  
     
  
  (2.8) 
where γ is the gyromagnetic ratio. Eq. (2.8) is then normalised (e.g. to the signal acquired 
without an applied gradient, Sg=0), giving the attenuation of the echo signal, E,  
 
0
exp( ).
g
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E bD
S
  (2.9) 
where    
2
3 .b g    D can then be determined using a non-linear regression of Eq. 
(2.9) to the echo attenuation data obtained at each gradient, as shown in Figure 17.  
 
 
Figure 17: Non-linear regression of the modified Stejskal-Tanner expression to the echo attenuation data 
of 0.16 M 2-nitroimidazole in D2O (298 K) obtained at 20 magnetic field gradients ranging from 0.001 – 
0.531 Tm
-1
 to obtain the diffusion coefficient of (8.19 ± 0.06) × 10
-10
 m
2
s
-1
.  
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Chapter 3. Magnetic Resonance Imaging 
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As NMR underpins the concepts of MRI, this chapter will build on the concepts of Chapter 2, 
and develop the fundamentals of MRI, which is the chosen method for in vitro observation of 
the synthesised hypoxia-targeting paramagnetic agent in this thesis. The MRI techniques that 
will be used later in this project will also be introduced. 
 Fundamental MRI Theory 3.1
Since 1973, the capabilities of NMR to map the spatial distribution of substances within an 
object has been developed as an imaging method [91-93]. Conceptual and technological 
advancements have allowed this imaging method, known as MRI to become one of the most 
important and versatile techniques in diagnostic medicine. Numerous imaging modalities are 
available for probing the human body. However, MRI is advantageous in that it is non-
invasive, does not use ionizing radiation and provides excellent soft tissue contrast.  
 One-Dimensional Imaging 3.1.1
In the previous chapter, it was explained how an NMR spectrum of a sample can be obtained. 
In this chapter, this concept is extended to obtain an image of the sample. To explain the 
concept of imaging, nuclear spin density, , must first be defined. Spin density refers to the 
number of nuclei in a given voxel, which in simple terms is a 3D equivalent of a pixel. 
Hence, a higher spin density results in higher signal intensity in an MRI image. The primary 
objective of imaging is to obtain information relating to  at each point, r, in the sample (i.e., 
(r)). To do so, the signals from nuclear spins need to be spatially differentiated. This can be 
done by applying a magnetic gradient, G, thus varying the external magnetic field in a 
defined direction [94]. As ω0 is proportional to the magnetic field experienced by the nuclei, 
the presence of a gradient allows ω0 to be expressed as a function of position, r [93],   
 0 0( ) .    r B G r   (3.1) 
Hence, with an application of a gradient, planes of constant field strength also become planes 
of constant resonance frequency. This relationship between the spatial domain and the 
frequency domain in the presence of a gradient forms the fundamental principles of MRI. It 
can be seen from Eq. (3.1) that a distribution of resonance frequencies will be observed in the 
NMR spectrum obtained in the presence of a gradient. 
This then allows  to be determined from the acquired NMR signal. Assuming G is 
constant, the acquired signal can be expressed as 
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The number of contributing nuclei in the constant-frequency plane will be proportional to the 
spectral amplitude at each frequency. Hence, the NMR spectrum of an object in the presence 
of a gradient corresponds to the projection of spins along the direction of the gradient, as 
shown in Figure 18.  
 
 
Figure 18: A schematic showing the use of a magnetic gradient to obtain a one-dimensional image in the 
form of an NMR spectrum, where the gradient and the external magnetic field are applied in the z-
direction. As the Larmor frequency becomes a function of the z-position due to the applied gradient, the 
NMR spectrum represents the distribution of the Larmor frequencies with the signal-amplitude at each 
frequency proportional to the number of spins in that frequency region. The 1D projection of ρ in the 
direction of the gradient is the image. 
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 Multi-Dimensional Imaging 3.1.2
The spatial information of one-dimensional objects can be accurately obtained from one-
dimensional images. However, one-dimensional projection images of two or three-
dimensional objects cannot be obtained, as the internal structures on different planes cannot 
be visualised. Therefore, imaging a two-dimensional object requires a procedure capable of 
identifying the coordinates of the volume elements that span two dimensions, and three in the 
case of three-dimensional objects. To account for the spatial axes in three dimensions, the 
application of three orthogonal gradients is required. These gradients can be described as 
slice selective, frequency encoding and phase encoding gradients.        
 
3.1.2.1 Slice Selection 
Slice selection is used to selectively excite the equilibrium magnetisation corresponding to a 
thin slice of an object. This involves applying a gradient (i.e., the slice gradient) along (in this 
case) the z-axis in conjunction with a frequency selective rf pulse. As depicted in Figure 19, 
the precession frequency of the spins is varied by the slice gradient, Gz, while only the spins 
with the selected frequency range are rotated into the transverse plane by the rf pulse. This 
results in only a limited part of the sample (i.e., the slice) being excited. As only the 
magnetisation from the slice is rotated into the transverse plane, it is the only contribution to 
the NMR signal. The thickness of the slice, Δz, can be adjusted by changing the frequency 
width of the rf pulse, Δωrf, and the strength of the applied gradient [93, 95], 
 .
rf
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z
G

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    (3.3) 
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Figure 19: A schematic representation of the slice selection process along the z-axis. The spins 
(represented by the arrows) are initially precessing at ω0. The application of the slice selective gradient 
causes the spins at different z-positions to precess at slightly different frequencies (ω1, ω2 and ω3). If a 
frequency selective rf pulse is applied at ω2, only the corresponding spins are rotated into the transverse 
plane, thus selecting the slice (denoted as the region in green on the 3D block).  
 
3.1.2.2  Frequency Encoding 
In this chapter, the frequency encoding gradient will be considered to be applied along the x-
axis. The application of the gradient results in the Larmor frequencies of the voxels becoming 
spatially dependent along the x-axis. This is similar to the effect that was discussed for one-
dimensional imaging with the exception that the spatial dependence is along a particular axis 
(in this case, x). Hence, Eq. (3.1) can be written as 
 
0 0( ) ,fx G x   B   (3.4) 
where Gf is the frequency gradient [93, 95]. This process is referred to as frequency encoding 
and is shown in Figure 20.  
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Figure 20: A schematic representation of frequency encoding along the x-axis following the application of 
a frequency encoding gradient. The red arrows denote the phase, which is not changed during the 
frequency encoding process.  
 
3.1.2.3 Phase Encoding 
As the frequency encoding gradient was considered to be applied along the x-axis, the phase 
encoding gradient will be considered to be applied on the y-axis. For such a gradient applied 
for a fixed time, t, the phase, , prior to signal acquisition can be expressed as a function of 
position y [93, 95], 
  0
0
( )
t
y B G y dt     (3.5) 
where G is the phase gradient. In the presence of a phase gradient, the nuclear spins will 
begin to precess at slightly different frequencies along the y-axis. This will in turn generate 
different spin phases along the y-axis. When the phase gradient is removed, the spin will 
return to the frequency that was present prior to the application of the phase gradient, but will 
maintain the phase differences that were generated by the phase gradient. This process is 
referred to as phase encoding (Figure 21).  
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Figure 21: A schematic representation of phase encoding along the y-axis following the application of a 
phase encoding gradient. The application of the gradient results in a change in the frequency and hence 
phase of the spins along the y axis. Removing the gradient returns the frequency to ω0, however the phase 
differences are retained as a function of position.  
 
  MRI Pulse Sequences 3.1.3
Two basic MRI pulse sequences, which form the basis of many others, are the spin-echo and 
gradient-echo pulse sequences, as shown in Figure 22 and Figure 23, respectively. It should 
be noted that in the discussion above and the following figures, the frequency, phase and slice 
gradients have been assumed to be along the x, y and z-axes, respectively. However, in 
practice, the three gradients can be applied along any three orthogonal directions.  
In the spin-echo sequence, the sign of the magnetic gradient is effectively negated by 
the π pulse, and phase dispersion due to magnetic inhomogeneities, chemical shifts and 
gradient-induced dispersions are refocussed [92, 96, 97]. In the gradient-echo sequence, only 
gradient-induced dispersions are refocussed.      
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Figure 22: A spin-echo MRI pulse sequence. A short negative slice selective gradient is applied following 
the π/2 rf pulse to refocus the magnetisation that has been dephased due to the application of the π/2 rf 
pulse. Equally spaced stacked lines have been used to represent the phase gradient to show that its 
magnitude is increased gradually when the sequence is repeated. In this sequence, the π pulse refocusses 
phase dispersion originating from magnetic inhomogeneities, chemical shifts and gradient-induced 
dispersions. TE is the echo time (i.e., the time between the application of the first rf pulse and the 
acquisition of the signal) and TR is the repetition time.  
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Figure 23: A gradient-echo MRI pulse sequence. The frequency-encoding gradients have been presented 
above and below the line to indicate antiphase gradients, which only refocus gradient-induced 
dispersions.  
 
 Image Reconstruction 3.1.4
The frequency encoded signal, which exists in the form of a time-dependent MR signal, is 
transformed into its different frequency components using Fourier transformation as shown in 
Figure 24. The relative amount of signal at each location along the frequency encoding 
gradient can be determined by mapping the amplitude of each frequency component. The 
range of frequencies across the defined field of view (FOV) in the frequency encoding 
direction is known as the receiver bandwidth and is determined by the amplitude required for 
the frequency encoding gradient [98]. 
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Figure 24: The frequency encoded signal is analysed by Fourier transformation, measuring the signal 
amplitude to map the contribution of each of the frequency components along the frequency encoding 
gradient (within the FOV). In the schematic, the x axis represents the frequency while the y axis 
represents the signal amplitude.    
 
A similar process cannot be used to decode the phase changes imparted by the phase 
encoding gradient, as Fourier transform can only analyse a signal that changes over time. To 
allow the phase data to be analysed by Fourier transformation, a number of signal echoes are 
generated by repeating the pulse sequences discussed earlier. The time interval between each 
repetition is the repetition time, TR. At each repetition, the slice selection and frequency 
encoding gradients are kept constant, while the phase encoding gradient is increased in equal 
increments from negative to positive, as depicted in Figure 25. The signal echo is measured 
for each phase encoding step and stored in a raw data matrix. After the signal for each of the 
phase encoding steps have been acquired and stored, it is analysed by a two-dimensional 
Fourier transform to decode both the frequency and phase information.  
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Figure 25: To acquire sufficient information for image reconstruction, the pulse sequence is repeated a 
number of times. At each repetition, the strength of the phase encoding gradient is increased from 
negative to positive. In the schematic, 7 increments are used for the phase encoding gradient. As the 
strength of the gradient is increased (either positive or negative), the amount of dephasing along the 
gradient also increases. As shown by the MR signals, the phase encoding gradient labelled 4 is of strength 
zero, resulting in no dephasing of the signal, hence producing a signal of maximum amplitude.  
 
3.1.4.1  Repetition Time and Image Acquisition Time 
In addition to determining the time required for MR images to be acquired, TR also affects 
image contrast. The number of phase encoding steps, Np, determines the number of pixels in 
the phase encoding direction of the reconstructed image. The spatial resolution of the image 
therefore depends on the number of phase encoding steps, which in most cases is limited by 
the image acquisition time, Taq,  
 .aq R pT T N    (3.6) 
Hence if greater spatial resolution in the phase encoding direction is required, the number of 
pixels in that direction must be increased, resulting in a greater number of repetitions and a 
longer Taq.  
3.1.4.2  k-Space 
The use of magnetic field gradients to generate and encode MR signals give rise to a 
particular relationship between the data points in the signal and the image. In image space, 
each pixel occupies a unique location. Similarly, each point of an MR echo signal belongs to 
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a unique location in a space referred to as k-space (Figure 26) [99]. Each point in k-space 
represents the particular spatial frequency contained within the corresponding image [98]. 
An image with a single spatial frequency can be pictured as a wave propagating 
across the image with bright and dark peaks and troughs. Peaks and troughs positioned far 
apart represent a low spatial frequency. This mainly contributes the signal content and 
contrast of the image. Conversely, peaks and troughs positioned close together represent a 
high spatial frequency. This defines the fine details, thus defining the spatial resolution of the 
image.    
 
Figure 26: The MR signal from each phase encoding step is stored in a raw data matrix called k-space 
(with axes kx and ky). The phase encoding gradient (depicted by the rectangular blocks) determines which 
line of k-space is filled. In this schematic, five different phase encoding gradients are used, resulting in 
five sets of data along the ky axis (depicted by the dotted lines). 
 
 Image Contrast and Weighting 3.1.5
The ability to generate contrast between different tissues types is one of the greatest 
advantages of MRI over other imaging modalities. The sources of contrast in MRI can 
emanate from nuclear spin relaxation times [100], spin density, chemical shift [101, 102], 
magnetic susceptibility [103, 104] and diffusion [105]. In MRI, it is also possible to 
experimentally further enhance the contrast of the image with respect to a particular factor, 
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such as longitudinal (i.e., T1) and spin-spin (i.e., T2) relaxation. This process is referred to as 
weighting. T1 and T2-weighting is of particular importance in enhancing contrast of different 
tissue types, as different types of soft tissue have different characteristic T1 and T2 relaxation 
times [98].     
The two key parameters to adjust to enhance contrast with respect to relaxation are TR 
and TE. Considering a gradient-echo experiment, the contrast between two tissues, A and B, 
can be expressed as the difference in the signal of each tissue,  
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where ABC  is the contrast between the two tissues.  
3.1.5.1  T1-Weighted Images 
To obtain effective T1-weighting, T2
*
 (i.e., effective T2) effects need to be minimised. This 
can be achieved by reducing TE, such that 
* ,
2
A B
ET T , thus reducing Eq. (3.7) to  
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  (3.8) 
3.1.5.2   T2-Weighted Images 
 Conversely, to obtain effective T2-weighting, T1 effects need to be minimised. This can be 
achieved by selecting a long TR ( 1RT T ). The exponential associated with T1 in Eq. (3.7) 
will then approach zero. Hence, (3.7) can be reduced to 
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As per the relationship in Eq. (3.9), optimal T2 contrast can be obtained by maximising CAB 
relative to TE [106].  
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Chapter 4. MRI Contrast Agents 
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  Introduction 4.1
In MRI, the relaxation rate of the water signal can be used as contrast to distinguish between 
different tissues. Such contrast can be enhanced using a contrast agent administered prior to 
scanning. These agents utilise paramagnetic metal ions and are evaluated on their ability to 
increase the relaxation rate of nearby water protons relative to their concentration. This 
evaluation is referred to as relaxivity. Whilst extensive research has looked into increasing 
the relaxivity of MRI contrast agents, very limited work has been undertaken to extend these 
properties to hypoxia-specific contrast agents (as mentioned in Chapter 1). Hence, the 
purpose of this chapter is to identify the most commonly used class of clinical contrast agents 
(i.e., positive contrast agents), and observe the different properties of the types of contrast 
agents in this class, thus determining the structure most favourable to be used in the 
development of the hypoxia-specific paramagnetic agents in this thesis.  
 Principles of MRI Contrast Agents      4.2
The concept of contrast enhancement in an MRI image was first demonstrated using 
manganese (II) salts in animal studies to achieve tissue discrimination [107]. Since then, 
Gd(III) (i.e., Gd
3+
), due to its seven unpaired electrons resulting in the shortening of the 
relaxation time of water protons, has become the most widely used metal centre for the 
production of paramagnetic contrast agents. This has led to Gd-based agents now becoming 
the most commonly used agents in the clinic [65, 108].  
While contrast agents containing Gd(III) increase both the longitudinal and transverse 
relaxation rates (i.e., 1 11R T  and 2 21R T , respectively), the relative change in R1 is much 
greater than R2 [109], hence such agents are predominantly visualised with T1-weighted 
imaging [65]. The most commonly used contrast agents, as shown in Figure 27, utilise 
polyaminocarboxylate ligands. In these agents, the Gd(III) centre is coordinated with nitrogen 
and oxygen donor atoms. The complexes shown in Figure 27 act as nonspecific extracellular 
agents. Following intravascular injection, such compounds distribute rapidly amongst plasma 
and interstitial spaces, after which are eliminated through the renal route with half-lives of 
approximately 1.6 h [110, 111].           
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Figure 27: Structures of commonly used commercial MRI contrast agents: a) Magnevist
®
 
[Gd(DTPA)(H2O)]
2
, b) Omniscan
®
 [Gd(DTPA-BMA)(H2O)], c) Dotarem
®
 [Gd(DOTA)(H2O)]
-
, d) 
OptiMARK
®
 [Gd(DTPA-BMEA)(H2O)], e) ProHance
®
 [Gd(HP-DO3A)(H2O)], and f) Gadovist
®
 
[Gd(DO3A-butrol)(H2O)] [112-114]. The above structures are classified as cyclic contrast agents, where 
the Gd ions are fully enclosed, in this case, by nitrogen and oxygen atoms. Alternatively, linear Gd 
contrast agents, where the Gd ions are not enclosed, are not discussed in the context of commercially 
available contrast agents in this thesis due to the recent suspension of such agents by the European 
Medicines Agency [115]. 
 
As mentioned previously in section 4.1, relaxivity (r1 or r2) is a measure of the 
efficiency of a contrast agent, and is defined as the change in the relaxation rate of the water 
protons normalised to its concentration, as given by 
 
1
,
[CA]
i
i
T
r
  
    (4.1) 
43 
 
where i = 1, 2 and [CA] is the concentration of the contrast agent. Relaxivity can be 
characterised with respect to T1 or T2 (i.e., r1 or r2, respectively) depending on whether the 
contrast agent is a positive (i.e., T1) or negative (i.e., T2) contrast agent. However, in practice, 
a simpler method to calculate r1 and r2 is to measure the T1 and T2, respectively of at least 
three dilutions of the contrast agent. In this way, the relaxivity is equal to the slope of 1/Ti 
versus [CA] (e.g. Figure 28), as can be seen by rearranging Eq. (4.2),   
  
,
1 1
CA ,i
i i d
r
T T
    (4.2) 
where Ti,d is the diamagnetic relaxation of the water protons (i.e., the relaxation of the 
solution without the contrast agent). 
 
 
Figure 28: Experimental results showing the 
1
H longitudinal (■) and transverse (●) relaxation rates for 
Magnevist plotted against concentration at 1 T (25 °C). From the slopes of the linear fits, r1 and r2 were 
determined to be 3.9 and 4.5 mM
-1
s
-1
, respectively. 
 
  Types of MRI Contrast Agents 4.3
As mentioned in the previous section, contrast agents can be classed as negative or positive 
contrast agents. Negative contrast agents usually have an r2/r1 as high as 10 or more [65]. 
This means that such agents reduce T2 a lot more than T1. Negative contrast agents are 
predominantly made from superparamagnetic iron oxide (SPIO) and induce negative contrast 
in an MR image by decreasing the signal intensity of the affected water protons [116, 117]. 
SPIO MR contrast agents are effectively used to visualise and detect lesions in the liver, as 
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SPIO particles are sequestered by phagocytic Kupffer cells in the normal reticuloendothelial 
system but not retained in lesions, which lack Kupffer cells [118].       
Positive contrast agents usually have an r2/r1 of approximately 1-2, comprising of 
paramagnetic metal ions chelated to multi-dentate ligands. These types of contrast agents 
induce a positive contrast by increasing the signal intensity of the surrounding water protons. 
The images produced by such agents exhibit hyper-intense regions via contrast agent 
accumulation, and thus are more commonly used in the clinics [119, 120]. For this reason, the 
following discussions deal with types of positive contrast agents.  
Positive contrast agents can be sub-divided into two categories based on their 
molecular weight: low and high molecular weight contrast agents, and these will be discussed 
below. As high molecular weight contrast agents are favourable for high relaxivities relative 
to low molecular weight contrast agents, such agents will then be discussed in terms of 
macromolecular and supramolecular contrast agents. By observing the properties of 
supramolecular contrast agents, in particular liposomes, it will be discussed why this type of 
contrast agent was chosen as the structure of choice for the synthesis of the hypoxia-specific 
paramagnetic agents in this thesis.     
  Low Molecular Weight Contrast Agents 4.3.1
Structurally, Gd-based contrast agents can be categorised as linear or macrocyclic agents 
based on the type of ligand. The ligands of linear agents are elongated and wrap around the 
Gd ion, while macrocyclic agents form a cage-like ligand structure, trapping the ion in a 
central cavity. Most of the current commercially available contrast agents take the form of 
either the linear-diethylenetriaminepentaacetic acid (DTPA) or cyclic-tetraazacyclododecane-
N,N,N,N-tetraacetic acid (DOTA) complexes of Gd(III). These contrast agents can be 
broadly classified as low molecular weight contrast agents (e.g., molecular weight ≈ 600 
[121]). However, the use of such contrast agents has also been linked with nephrogenic 
systemic fibrosis, especially in patients with acute renal failure [122, 123]. It is suspected that 
the Gd-ligand complex dissociates due to the prolonged clearance as a result of renal failure. 
This further emphasises the need for more stable contrast agents [122]. Whilst low molecular 
contrast agents have been used clinically, the use of high molecular weight contrast agents 
(e.g., Gadomer: molecular weight ≈ 40,000 [121]) are more favourable in obtaining higher 
relaxivities. This will be discussed in the following section, and such contrast agents are the 
focus of this chapter. 
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  High Molecular Weight Contrast Agents 4.3.2
The relaxivity of a contrast agent is affected by the reorientational correlation time (τR), mean 
water residency time (τm), electronic relaxation times (Tie where i = 1,2) and hydration 
number (q). Increasing the molecular weight of a contrast agent slows down the molecular 
reorientation of the contrast agent, resulting in a longer τR and thus, a higher relaxivity. 
Hence, such contrast agents are desired in the clinics as it enables for better contrast at low 
doses [124]. High molecular weight contrast agents take the form of macromolecular or 
supramolecular contrast agents, and will be discussed in the following sections. 
4.3.2.1 Macromolecular Contrast Agents 
Macromolecular contrast agents are formed by the conjugation of chelates onto 
macromolecular carriers. This involves attaching low molecular weight Gd chelates to large 
molecules such as proteins or polymers. The chelates can also be incorporated within 
dendrimers, zeolites, fullerenes and nanotubes to form macromolecular contrast agents. 
Irrespective of the method, the molecular reorientation of the contrast agent is reduced (i.e., 
restricted by the larger molecule), thus resulting in higher relaxivities.  
Macromolecular contrast agents can be classified as block, graft, dendritic or micellar 
macromolecular contrast agents according to the position of the Gd(III) chelates in the 
carriers [125]. In block agents, the condensation polymerisation of DTPA dianhydride with 
diol or diamine monomers is used to incorporate Gd chelates into the polymer [125]. In graft 
and dendritic agents, the reaction of bifunctional contrast agents with reactive groups on the 
polymer is used to conjugate the Gd chelates, while emulsion polymerisation is used to 
produce micellar agents [125]. Irrespective of the structure, macromolecular contrast agents 
deliver smaller payloads of Gd(III) ions than supramolecular agents. Hence, supramolecular 
contrast agents are favoured for use in MRI, and are the focus of this thesis, and are discussed 
below.   
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Figure 29: Schematic structures of the four classes of macromolecular contrast agents: a) block, b) graft, 
c) dendritic and d) micellar (with the structure depicted by the black circle representing an aggregate of 
surfactant molecules dispersed in a liquid colloid).  
 
4.3.2.2 Supramolecular Contrast Agents 
Supramolecular aggregates, such as micelles and liposomes, are obtained by spontaneous 
assembling of amphiphilic molecules in aqueous solution. These amphiphilic molecules 
consist of a hydrophobic and a hydrophilic moiety. In water, the hydrophobic associative 
interactions of the tails and the repulsive interactions between the hydrophobic head groups 
self-assemble these amphiphilic molecules into well-defined structures [126]. A wide variety 
of factors can be varied when designing the hydrophobic and hydrophilic moieties of 
amphiphilic molecules. The hydrophobic moiety can be varied in length, containing multiple 
chains. This thereby alters the size of the hydrophobic component, hence changing the ratio 
(with respect to size) between the hydrophobic and hydrophilic components. Furthermore, the 
hydrophilic head-group can be varied in size and charge, thus altering the molecules between 
ionic and non-ionic amphiphiles. 
The type of supramolecular aggregates that form in solution can be predicted based on 
the steric relationship of the head-group and the side arm [127], 
 ,
v
SP
al
   (4.3) 
where SP is the surfactant parameter, v and l are the volume and length, respectively, of the 
hydrophobic chains, and a is the surface area of the hydrophilic head-group. Amphiphiles 
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with SP ≈ 1 are likely to yield flat structures (e.g., vesicles or planar lamellar) due to the 
balance in sizes between the head and tail groups [128]. Amphiphiles with SP < 1 are likely 
to form structures curved towards the hydrocarbon chain (e.g., cubic phases), while 
amphiphiles with SP > 1 are likely to form structures curved towards water (e.g., inverse 
hexagonal structures [129]) [128]. These characteristics, along with other parameters such as 
pH, concentration, temperature and ionic strength, determine whether micelle-like structures, 
such as cylindrical, spherical or ellipsoidal micelles or bilayer-like structures, such as vesicles 
or liposomes, are formed [120]. 
Micellar aggregates are characterised by their unique core shell structure. In an 
aqueous solution, the inner core is formed by the segregation of the hydrophobic component 
of the amphiphilic molecules from the aqueous exterior. The hydrophilic components form 
the outer shell. The formation of micelles is driven by a decrease of free energy within the 
system. This results from the re-establishing of the hydrogen bond network in water 
following the removal of hydrophobic fragments from the aqueous solution. In addition, the 
formation of micelles results in Van der Waals interactions between hydrophobic moieties in 
the core [120, 130]. Micelles usually range in size from 5 to 50 nm [120]. 
Conversely, liposomes are self-enclosed artificial phospholipids vesicles, varying in 
size from 25 to 1000 nm [131]. Liposomes can be classified as unilamellar (i.e., one lipid 
bilayer) or multilamellar (i.e., multiple lipid bilayers), as shown in Figure 30. The preparation 
of liposomes usually involve the addition of cholesterol, which is used to stabilise the lipid 
bilayer. The addition of cholesterol also influences the water permeability of the liposome 
membrane [132]. However, water permeability is predominantly affected by the length of the 
phospholipid alkyl chain and the unsaturation of the hydrocarbon chain [120]. 
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Figure 30: Liposomes can be classified depending on the number of lipid bilayers: a) multilamellar or b) 
unilamellar liposomes. Unilamellar liposomes range from approximately 25 – 200 nm (diameter) in size, 
whilst multilamellar liposomes can be up to 1000 nm [131].  
 
The biodistribution of micelles and liposomes are controlled by easily altered 
physicochemical properties such as membrane composition, size or surface charge [120, 133-
135]. This allows for the attainment of favourable pharmacological characteristics, thus 
making supramolecular aggregates excellent candidates as possible carriers for MRI contrast 
agents. Attaching a Gd-based contrast agent to a supramolecular aggregate would allow to 
enhance contrast efficacy and change the pharmacokinetic properties of the contrast agent. 
Studies dating back to the 1980s [136-138] have used two main approaches in the 
development of liposomal contrast agents. One approach is to entrap the contrast agent within 
the central region of the liposome [136], while the other incorporating the contrast agent in 
the lipid bilayer of the liposome [137, 138] (Figure 31).  
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Figure 31: Two main approaches in the development of liposomal contrast agents: a) the contrast agent 
(red) is trapped within the central region of the liposome, and b) the contrast agent is incorporated into 
the lipid bilayer of the liposome.  
 
Studies entrapping the contrast agent within the centre of the liposome have shown a 
low relaxivity, of approximately two to five times lower compared to free Gd complexes 
[139]. This is believed to be due to the limited exchange of bulk water with the contrast 
agent, resulting from the low water permeability of the liposomal membrane [136, 140, 141]. 
On the contrary, incorporating the contrast agent in the lipid bilayer and localising it on the 
liposome surface, increases the relaxivity of the contrast agent relative to both encapsulation 
method complexes and low molecular weight complexes [142], hence presents an ideal 
design to be used in the development of new contrast agents.   
The Nuclear Magnetic Relaxation Dispersion (NMRD) profile of supramolecular 
contrast agents typically show a peak at higher frequencies, indicating an increase in 
reorientational correlation times relative to low molecular weight contrast agents. More 
importantly, these peaks occur at clinical relevant magnetic field strengths (≈1 T), meaning 
that the highest relaxivities will be able to be utilised in the clinic. The use of supramolecular 
contrast agents further enhances the total relaxivity per contrast agent particle as the ratio of 
Gd(III) complexes per supramolecular particle is in the order of 50:1 for small micelles and 
upwards of several thousand for liposomes [120].      
As mentioned previously, low water permeability of the liposomal membrane results 
in low relaxivities. This can be increased by using smaller liposomes, thus improving the 
exchange with external bulk water. The reduction in relaxivity in larger liposomes is most 
likely due to the reduced surface area to volume ratio and the presence of multilamellar 
bilayers, which slow water exchange between the interior and the exterior of the liposome 
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[136, 140]. Hence, small, unilamellar liposomes with a permeable bilayer would be an 
optimal formulation for the purpose of increased relaxivities. However, careful consideration 
needs to be made with such formulations as permeable liposomes tend to be less stable than 
those with more rigid bilayers. 
Furthermore, liposomes can be surface functionalised with targeting ligands to 
enhance tumor selective targeting. Despite the demonstration of clinically useful anti-tumor 
activity with passively targeting liposomes [143, 144], further specificity for the tumor cell 
can be achieved via ligand-mediated targeting (more commonly referred to as active 
targeting). Use of such ligand-mediated targeting in drug delivery has yielded significantly 
increased drug delivered to target cells compared to when free drugs or passive targeting was 
used. Such a concept can be extended to the development of contrast agents which target 
tissue hypoxia. 
Hence, for the reasons discussed above, in particular, the biocompatibility, synthesis 
simplicity, high relaxivity properties and targeting capabilities, supramolecular aggregates in 
the form of liposomes will be the structure of choice used in the development of the hypoxia-
specific paramagnetic agents in this thesis, as will be detailed in Chapter 7. 
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NMR Diffusion Measurements of Exchanging Systems, Concepts in Magnetic Resonance 
Part A, 2018 (in press).  
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 Introduction 5.1
Being able to characterise binding and exchange is fundamental to understanding chemical 
reactions. For example, the biological activity of drugs at the molecular level corresponds to 
the binding of small molecules to macromolecular receptors, such as protein-ligand 
interactions, and lies at the heart of pharmacology [145]. NMR spectroscopy is widely used 
to study binding and exchange in chemical and biological systems due to its general 
applicability and non-invasive nature [146-149]. A range of NMR techniques have been used 
to study exchange in a diverse range of systems, with a particular emphasis on solution-state 
NMR to probe protein-ligand interactions [149, 150]. All NMR techniques rely on some 
NMR observable that is sensitive to exchange such as chemical shift, relaxation (including 
nuclear Overhauser effects), saturation transfer or diffusion. 
This chapter focusses on the use of diffusion measurements to study (intermolecular) 
exchange. The mathematical framework for analysing such data is provided by the Kärger 
equations [151-153]. In fact, the Kärger model and adaptations have found wide application 
to chemical and biological systems including brain imaging [154-156]. Here, a detailed 
derivation of these equations for the case of two freely diffusing exchanging species is 
presented along with the simplifications that result in the slow and fast exchange limits. 
Considerable emphasis is given to the physical interpretation and limitations of these 
equations. With the intention of studying ligand binding using NMR diffusion measurements 
in the following chapter of this thesis, some consideration is given to the analysis of protein-
ligand binding using diffusion NMR. Finally, the extension of the Kärger equations to cover a 
three-state model is briefly considered. First, however, it is considered how the Bloch 
equations, exchange equations and diffusion equation can be combined in various ways to 
describe these phenomena. 
 The Bloch Equations, Chemical Exchange and 5.2
Diffusion 
Here introduced in turn are: (1) the Bloch equations describing the evolution of the nuclear 
magnetisation in the presence of a magnetic field, magnetic gradients and rf pulses; (2) the 
equations governing chemical exchange in situations involving conformational changes or 
intermolecular binding; and (3) the diffusion equation in the differential form. Each of these 
equations is then reduced to a simpler form in terms of the complex magnetisation 
M(z,t) = Mx(z,t) + iMy(z,t), which is more suitable for the development of the theory later in 
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the chapter. These three equations will be combined together in various ways in later 
sections.
 
 The Bloch Equations 5.2.1
The evolution of nuclear magnetisation for an uncoupled population of spin-half nuclei can 
be described by the Bloch equations [157, 158], 
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where M(r,t) = Mx(r,t)i + My(r,t)j + Mz(r,t)k is the macroscopic magnetisation density of the 
population; B(t) is the magnetic field – typically this is of the form 
B(r,t) = (B0 + G(t)·r)k + Brfcos(ωrft + ϕ)i where B0 is the strength of the main magnetic field 
and, if a gradient is present, its magnitude and direction are given by G(t) (r denotes the 
position of the nuclear population); Brf is the magnitude of the rf pulse (and is significantly 
smaller than B0), ωrf is its frequency and ϕ is its phase. The effects of the rf pulse do not need 
to be considered here and this term will be ignored from now on. It can also be assumed the 
gradient is along the longitudinal direction and to be of the form G(t) = gf(t)k, where g is the 
strength of the magnetic gradient and f(t) is a temporal shape function (having a maximum 
value of one). In this case, B(r,t) only has a component in the longitudinal (k) direction and 
the Bloch equations simplify to, 
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This is a set of coupled differential equations – but only the transverse components Mx(r,t) 
and My(r,t) are coupled together. Thus, if the interest is only in the evolution of the transverse 
magnetisation under delays and gradients (and also under 180° pulses), the transverse 
components of Eqs. (5.2) can be written in complex form by defining 
M(r,t) = Mx(r,t) + iMy(r,t) and noting, 
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where ω0 = –γB0 (i.e., the Larmor frequency) and the x and y directions have been eliminated 
since it can be assumed M is only a function of z and t. By making the replacement 
M → Mexp(iωrft), Eq. (5.3) becomes, 
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where ωrf is the precession frequency of the rotating reference frame (this can be any 
frequency selected). When radiofrequency pulses are involved it’s convenient to set ωrf equal 
to the frequency of the rf pulse (the subscript rf can then be interpreted either as rotating 
frame or radiofrequency). For the purposes of this chapter, it is convenient to choose ωrf as 
ω0, which eliminates the first term on the right-hand-side from Eq. (5.4). The last term can 
also be eliminated by making the replacement M → Mexp(–t/T2) yielding, 
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 Chemical Exchange 5.2.2
Chemical exchange, in the NMR context, refers to any process where a nucleus exchanges 
between two or more environments in which its NMR parameters differ. Chemical exchange 
can be categorised as intramolecular exchange, where a molecule undergoes a conformational 
change, or intermolecular exchange, where the molecule binds to another molecule, such as a 
protein (see Figure 32). 
 
 
Figure 32: Two types of chemical exchange: (a) intramolecular exchange, showing a conformational 
change of the molecule cyclohexane, and (b) intermolecular exchange, showing the binding of one 
molecule to another. Diffusion NMR is particularly applicable to studying intermolecular exchange. 
 
Consider an exchanging chemical system,  
 
 A BA
B
k
k
,  (5.6) 
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where A and B represent different conformations or binding states of the same molecule with 
rate constants kA and kB. The quantities of molecules in forms A and B, denoted [A] and [B], 
respectively, and measured in moles are given by, 
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However, this system needs to be viewed from the NMR observable perspective, where both 
A and B contain NMR observable nuclei (e.g., 
1
H) and assume that some subset of these are 
labelled (i.e. have, on average, a spin aligned along some direction denoted by a unit vector 
Mˆ ). Now [A] and [B] denote the number of moles per unit volume of these labelled nuclei. 
Then the macroscopic magnetisation densities corresponding to the NMR active nucleus are 
proportional to [A] and [B], respectively, and aligned along Mˆ , giving, 
 
 
 
   
 
   
,
, , ,
,
, , ,
A
A A B B
B
A A B B
d t
k t k t
dt
d t
k t k t
dt
  
 
M r
M r M r
M r
M r M r
  (5.8) 
 
where MA and MB are the magnetisation densities corresponding to states A and B, 
respectively. Furthermore, at equilibrium (i.e., when MA(r,t) = M0Ak and MB(r,t) = M0Bk) the 
time derivatives in Eq. (5.8) are zero, giving, 
 
 0 0A A B Bk M k M .  (5.9) 
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The fractional populations in pools A and B at equilibrium are denoted by PA and PB, 
respectively. Since these are fractional populations, 
 
 1A BP P  .  (5.10) 
 
Also, since PA and PB are proportional to M0A and M0B, respectively, with the same constant 
of proportionally, Eq. (5.9) gives (the principle of detailed balance), 
 
 A A B Bk P k P .  (5.11) 
 
If the interest is only in the transverse magnetisation and the magnetisation is 
considered to be independent of x and y, M (z,t)=Mx(z,t) + iMy(z,t) can be set, giving, 
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The rate constants kA and kB are related to the average lifetimes τA and τB of the two 
sites by kA = τA
–1
 and kB = τB
–1
. Eq. (5.12) can therefore be written more simply as, 
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and Eq. (5.11) as, 
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 Diffusion 5.2.3
In the context of this chapter, it will be useful to model diffusion using the diffusion equation 
(Fick’s second law; which is mathematically equivalent to the equation for heat conduction) 
(e.g., refs.[159-161]), 
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where ϑ is the concentration. In addition to describing mutual diffusion – that is diffusion in 
the presence of a chemical potential gradient, e.g. the diffusion of some substance A within 
another substance B where ϑ  , tr  represents the concentration of A in B at position r and 
time t – Eq. (5.15) can also be used to describe self-diffusion, where the chemical potential 
gradient equals zero. For the measurement of self-diffusion ϑ  , tr  can represent the 
concentration of some non-invasive label at position r and time t. This label in NMR is the 
nuclear spin state represented by the magnetisation density M, giving, 
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If the magnetisation is initially independent of x and y, then it will remain so and M can be 
considered to be a function of only z and t. Eq. (5.16) then becomes, 
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Furthermore, if only the transverse magnetisation is of interest (which is often the case), then 
the equations for Mx and My can be combined into one equation, 
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where M(z,t) = Mx(z,t) + iMy(z,t). 
 Probing Binding and Exchange Using Diffusion 5.3
NMR 
 Diffusion and its Measurement 5.3.1
D is an NMR observable that can be used to probe binding and exchange. As discussed in 
Chapter 2, a diffusion coefficient can be physically interpreted through the Stokes-Einstein-
Sutherland equation, which in essence states that the larger molecules diffuse more slowly 
than the smaller molecules. Hence, if a species is exchanging and becoming larger (e.g., self-
association) or effectively larger (e.g., a ligand binding to a protein) then this will be reflected 
in the measured diffusion coefficient. The effects of exchange also affect the measured 
diffusion coefficient as will be illustrated below. 
There are many NMR sequences that can be used to measure diffusion [76]. Here, the 
PGSE method which is the progenitor of most of the other sequences is considered. 
Combining the Bloch equations (Eq. (5.5)) with the diffusion equation (Eq. (5.18)) provides 
an equation that describes how the magnetisation evolves in the presence of a gradient while 
diffusion is occurring. The combination is straightforward: the time derivative of the 
transverse magnetisation is simply given by the right-hand-side of Eq. (5.5) added to the 
right-hand-side of Eq. (5.18), viz. [162], 
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These equations are known as the Torrey-Bloch equations and can be used to compute the 
signal attenuation resulting from diffusion occurring during the sequence.  
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In brief, NMR diffusion measurements are conducted in using a spin-echo or 
stimulated echo pulse sequence modified to include a pair of magnetic pulsed field gradients 
of duration  and amplitude g separated by a delay Δ. The first gradient pulse winds the spin 
magnetisation into a helix and the second gradient pulse unwinds the helix. The pitch of the 
helix is given by q
-1
 (m) where q is defined by 
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Recall that the magnetic gradient is a vector quantity and that g (or equivalently q) defines 
the direction in which diffusion is measured (some nice illustrations of this are given in 
ref.[163]). In an isotropic system such as the one considered here, the same result will be 
obtained irrespective of the direction of the gradient. However, were the system to be 
anisotropic this would not be the case. 
 
Diffusion occurring between (and during) the gradient pulses causes the 
magnetisation helix to attenuate so that after the second gradient pulse the unwound 
magnetisation is of a reduced magnitude than would have been the case had there been no 
diffusion. This results in acquisition of a smaller signal S. The degree of attenuation depends 
on D, g,  and . The spin-echo signal for a freely diffusing species is given by [76, 90, 164], 
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(which, as stated previously, can be computed from the Torrey-Bloch equations) where M0 is 
the initial magnetisation. The /3 term is the correction factor for diffusive attenuation that 
occurs during the gradient pulses (i.e. during the winding and unwinding of the magnetisation 
helix). Eq. (2.8) is typically normalised to the signal acquired without an applied gradient 
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(Sg=0) to remove the attenuation of the spin-spin relaxation, giving the attenuation of the echo 
signal, E,  
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Analysis for the stimulated echo based pulse sequence is very similar except that Eq. 
(2.8) must be modified to also include the effects of spin-lattice relaxation during the delay τ2 
where the magnetisation is longitudinal. However, normalising the signal to get the 
attenuation E in the same manner as used for the PGSE sequence results in exactly the same 
attenuation expression as PGSE (Eq. (2.9)). Experimentally, the molecular self-diffusion 
coefficient can be measured by conducting a series of measurements with different g values. 
D can then be determined using non-linear regression of Eq. (2.9) onto the echo attenuation 
data (i.e., E versus g. Δ defines the timescale of the diffusion measurement. 
In the short gradient pulse (SGP) approximation in which it is assumed that the 
gradient pulses are infinitely short (but g is finite), the expression for the signal and 
attenuation take the simpler forms 
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and   2exp 2E q D   .  (5.24) 
 
Experimentally it is normally impossible to even closely approximate the requirements for 
the SGP condition. However, the analysis of the echo attenuation is greatly simplified in the 
SGP condition since the effects of diffusion during the gradient pulse (i.e., during the  
periods) can be neglected. This is why Eqs. (5.23) and (5.24) lack the /3 term found in Eqs. 
(2.8) and (2.9) that corrects the attenuation for the effects of diffusion during  . Note, 
however, that the correction for diffusion during the gradient pulses is extremely difficult to 
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compute analytically for anything more complicated than straight free diffusion of a single 
non-exchanging species (e.g., see ref.[165]). 
Now consider a system in which a molecule is undergoing exchange, where it is 
assumed that binding is between free and bound states. If the exchange is slow on the 
timescale of Δ (i.e., Δ << τA, τB), then during the diffusion measurement timescale Δ it will 
appear as though there are two species present, the free species and the bound species. Then 
the signal intensity should be the signal from the free species added to the signal from the 
bound species, viz., 
  
      2 2exp 2 exp 2b b f fS P q D P q D       ,  (5.25) 
 
where Pb and Pf are the populations of the bound and free species, respectively, and Db and Df 
are their respective diffusion coefficients. The effects of spin relaxation during the PGSE 
sequence have been ignored. 
Now assume that the exchange is fast – so during the diffusion measurement period Δ 
there are many exchanges back and forth between the free and bound states (i.e., Δ >> τA, τB). 
Thus, it appears that there is one diffusing species with a population-weighted diffusion 
coefficient, 
  
 f f b bD P D P D  . (5.26) 
 
What is not so clear is what diffusion measurements should yield in the case of 
intermediate exchange between the fast and slow limits, and even under what conditions the 
fast and slow limits can be said to hold. To answer these questions, the Kärger equations must 
be developed [151-153]. 
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 The Two-Site Kärger Model for Two Freely Diffusing 5.3.2
Species 
The two-site Kärger model describes the signal intensity following a PGSE experiment for a 
diffusing species that can exist in both a free and a bound state. To make the analysis more 
mathematically tractable the equations are developed within the SGP approximation (see 
Section 5.3.1) although efforts have been made to extend their validity beyond the SGP 
approximation [166]. Thus, diffusion and exchange are ignored during the gradient pulses 
and the model becomes an analysis of the signal attenuation occurring during the Δ period 
where the magnetisation is in the form of a helix. The Kärger model can be derived by 
combining the Bloch equations (Eq. (5.4)), with the equations governing chemical exchange 
(Eqs. (5.13)) and with the diffusion equation (Eq. (5.18)). To recap: the diffusion equations 
are, 
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the exchange equations are, 
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and the Bloch equations (in the form useful here are), 
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M represents the complex-valued transverse nuclear magnetisation (with Mf being the 
component belonging to the free state and Mb belonging to the bound state); Df and Db are the 
diffusion coefficients for the free and bound states, respectively; τf and τb represent the 
lifetimes in the free and bound states, respectively; ω0f and ω0b are the Larmor frequencies of 
the resonance of interest for the free and bound states of the molecule; and T2f and T2b are the 
relaxation times of the resonance of interest for the free and bound states of the molecule, 
respectively. The time rate of change of Mf and Mb can be obtained by adding the right-hand-
sides of Eqs. (5.27), (5.28) and (5.29), viz., 
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If ω0f = ω0b then ωrf can be set equal to both ω0f and ω0b which eliminates the first term in 
both equations in Eq.  (5.30), giving, 
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This elimination can only occur if the chemical shifts of the free and bound states are 
identical. This is a not uncommon occurrence (e.g., refs. [84, 167]). Different chemical shifts 
complicate the analysis, and will not be considered here. A similar elimination of the last 
term can be made in Eqs. (5.31) and (5.32) if T2f = T2b. So in effect, the Kärger equations will 
only rely on the combination of the diffusion and exchange equations (Eqs. (5.27) and (5.28)) 
with all the Bloch equation terms vanishing under the conditions being considered. 
Eqs. (5.31) and (5.32) describe the evolution of the transverse magnetisation under 
diffusion, exchange between the free and bound states, and the effects of spin-spin relaxation. 
Given an initial magnetisation profile for the free and bound states, Mf(z,0) and Mb(z,0), Eqs. 
(5.31) and (5.32) can be used to get the transverse magnetisation profile at a later time. 
However, the real interest is in determining the degree of signal attenuation of a 
magnetisation helix after time Δ (at this time the helix is unwound and the signal intensity 
measured). Fortunately, it is quite easy to obtain ordinary differential equations that describe 
such signal attenuation by substituting, 
 
      , exp 2f fM z t S t iqz   (5.33) 
and, 
      , exp 2b bM z t S t iqz ,  (5.34) 
 
into Eqs. (5.31) and (5.32) where q is defined as in Eq. (5.20). 
All the information about the magnitudes of the helices is contained in Sf(t) and Sb(t). 
If the helix is unwound at time Δ and a signal acquired, then the signal strength is 
proportional to Sf(Δ) and Sb(Δ). The equations governing Sf(t) and Sb(t) are called the Kärger 
equations, which can be obtained by making the substitutions given above (Eqs. (5.33) and 
(5.34) in Eqs. (5.31) and (5.32) and then dividing out the factor of exp(2πiqz)), viz., 
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and, 
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where G =(2q)2. 
According to these equations, the change in the signal intensity of the free species 
over time, t, is a result of the signal intensities lost due to diffusion and T2 decay,  and the 
intensities added via exchange (i.e., signal intensity from the bound species) [168]. This is 
represented schematically in Figure 33. 
  
 
Figure 33: Sf and Sb represent the signal intensities of a free and bound species, respectively. The two 
species in exchange are linked by the forward and reverse rate constants. GD represents the rate constant 
associated with signal intensity loss due to diffusion and 1/T2 the rate constant associated with signal 
intensity loss due to spin-spin relaxation over time. 
 
If it is assumed that T2 is either the same for the free and bound complex (i.e., T2f = T2b = T2) 
or is significantly long relative to the timescale of the experiment [76], the equations can be 
simplified to, 
 
 
 
 
   f f b
f f
f b
dS t S t S t
GD S t
dt  
      (5.37) 
and 
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 
 
   fb b
b b
b f
S tdS t S t
GD S t
dt  
      (5.38) 
 
by making the substitutions Sf(t) → Sf(t)exp(–t/T2) and Sb(t) → Sb(t)exp(–t/T2) in Eqs. (5.37) 
and (5.38) in the first case and by neglecting the relaxation terms in the second case (i.e., 
approximating 1/T2 as zero). 
 Solving the Two-Site Kärger Equations for Two Freely 5.3.3
Diffusing Species 
5.3.3.1 General Solution 
To solve the two-site Kärger equations, Eqs. (5.37) and (5.38), which are two coupled first-
order differential equations, the first task is to uncouple them. Making Sb(t) the subject of Eq. 
(5.37) gives, 
 
  
 
 
 
,
f f
b b f f
f
dS t S t
S t GD S t
dt


 
   
  
  (5.39) 
which upon differentiation yields, 
 
 
     2
2
1
.
f fb
b f
f
d S t dS tdS t
GD
dt dt dt


  
     
   
  (5.40) 
 
Substituting Eq. (5.39) into Eq. (5.38) and simplifying yields, 
 
 
 
 
 
  0fb b b f f
dS tdS t
GD S t GD S t
dt dt
    .  (5.41) 
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Eqs. (5.39) and (5.40) are then substituted into Eq. (5.41) and simplified, 
  
 
   
 
2
2
2
1 1
( ) 0
f f fb
f b b f f
f b f b
d S t dS t GDGD
G D D G D D S t
dt dt   
   
             
   
.(5.42) 
 
Eq. (5.42) is a second order homogenous linear ordinary differential equation (ODE) (e.g., 
Ref.[161]). Note that it is uncoupled from Sb(t). A similar expression can be obtained for 
Sb(t), but note that Sb(t) can be obtained from Eq. (5.39) by substituting the solution for Sf(t). 
The next task is to solve Eq. (5.42). Substituting Sf(t) = exp(λt) into Eq. (5.42) and 
dividing out the common factor exp(λt) gives a characteristic equation of the form 
aλ2 + bλ + c = 0, viz., 
 
 
2 21 1( ) 0.
fb
f b b f
f b f b
GDGD
G D D G D D 
   
   
             
   
  (5.43) 
 
The roots of the above quadratic equation can then be determined by considering 
2
1 2
4
,
2
b b ac
a
 
  
 , where 1a  , 
1 1
( )f b
f b
b G D D
 
     and 
2 .
fb
b f
f b
GDGD
c G D D
 
     
The general solution is, 
 
 1 1 2 2( ) exp( ) exp( )fS t C t C t   , (5.44) 
where, after simplification, 
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2
1 2 2
1 1 1 1 1 1 4
, ( )
2
f b b f
f b b f b f
G D D G D D
G G
 
     
 
                       
      
,  (5.45) 
and C1 and C2 are arbitrary constants. 
Eq. (5.44) with Eq. (5.45) give the general solution to Eq. (5.42). The final step is to 
find appropriate expressions for C1 and C2 in terms of the initial populations of the free and 
bound states. 
At t = 0, the signal of the free and bound components are proportional to the free Pf 
and bound Pb populations, respectively. Since only relative signal amplitudes are of concern, 
the constant of proportionality can be set to unity and the signals at t = 0 are then given by 
Sf(0) = Pf and Sb(0) = Pb. From Eq. (5.44), it is seen Sf(0) = C1 + C2. Therefore, 
 
 1 2fC P C  .  (5.46) 
 
Writing λ1 = –GD1 and λ2 = –GD2, Eq. (5.44) can be written as, 
 
 2 1 2 2( ) ( )exp( ) exp( )f fS t P C GD t C GD t     ,  (5.47) 
where, 
 
 
2
1 2
1 1 1 1 1 1 1 4
2
f b b f
f b b f b f
D D D D D
G G G     
 
                      
      
  (5.48) 
and  
 
2
2 2
1 1 1 1 1 1 1 4
2
f b b f
f b b f b f
D D D D D
G G G     
 
                      
      
.  (5.49) 
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Now to obtain an expression for C2. The initial rate of change of the free signal with 
respect to time is obtained by differentiating Eq. (5.47) with respect to time and evaluating at 
t = 0, viz., 
 
 1 2 2 2
0
( )
( )
f
f
t
dS t
GD P C GD C
dt

    . (5.50) 
 
Eq. (5.37) can also be evaluated to obtain the initial rate of change of the free signal with 
respect to time, 
 
 
0
( )f f b
f f
f bt
dS t P P
GD P
dt  

    ,  (5.51) 
 
where Sf(0) and Sb(0) have been replaced by Pf and Pb, respectively. Note, however, Eq. 
(5.14) means that the last two terms on the right hand side of Eq. (5.51) vanish. Thus 
equating the right hand sides of Eqs. (5.50) and (5.51) and solving for C2 gives, 
 
 
1
2
2 1
f f fD P D P
C
D D



.  (5.52) 
 
If Eq. (5.38) is solved for ( )bS t , an equation identical in form to Eq. (5.47) can be derived,  
    
 
' '
2 1 2 2( ) ( )exp( ) exp( ).b bS t P C GD C GD         (5.53) 
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Applying the same method used to determine 2C , 
'
2C : 
 
' 1
2
2 1
.b b b
D P D P
C
D D



  (5.54) 
Therefore, the solutions for the free and bound signal intensities are, 
 
 
2 1
1 2
2 1 2 1
( ) exp( ) exp( )
f f f f f f
f
D P D P D P D P
S t GD t GD t
D D D D
 
   
 
  (5.55) 
and 
 
2 1
1 2
2 1 2 1
( ) exp( ) exp( )b b b b b bb
D P D P D P D P
S t GD t GD t
D D D D
 
   
 
, (5.56) 
 
respectively. The total attenuation E is defined to be the sum of the signal originating from 
the free and bound states at time t = Δ (the time at which the magnetisation helix is actually 
unwound and the signal acquired), 
 
 ( ) ( )b fE S S    ,  (5.57) 
giving, 
 1 1 2 2exp( ) exp( )E P GD P GD      , (5.58) 
where, 
 
2 2
1
2 1
f f f b b bD P D P D P D P
P
D D
  


  (5.59) 
and 
 
1 1
2
2 1
f f f b b bD P D P D P D P
P
D D
  


.  (5.60) 
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Note that P1 + P2 = Pf + Pb. Now that the general solutions have been developed, Eq. (5.58) 
can be examined in the limits of slow and fast exchange. 
5.3.3.2 Slow Exchange Limit 
For ,b f   , the second order term,  24 b fG     in Eqs. (5.48) and (5.49), approaches zero 
and D1 and D2 become, 
 1
1
f
f
D D
G
    (5.61) 
and 
 2
1
b
b
D D
G
    (5.62) 
Substituting Eqs. (5.61) and (5.62) into (5.58) yields the solution in the slow exchange limit, 
 
2
2 1
12 2
2 1
1 1
exp (2 ) exp (2 )
2 2
b b f f
b b f f
f b
f b
D D P D P
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D D
D P D P D
q D q D
q D D q
 
   
  
  
 
        
                        
  (5.63) 
5.3.3.3 Fast Exchange Limit  
When , 0b f   ,  1 1f b   , hence D2 in Eq. (5.58) becomes infinite (see the 
definition of D2 in Eq. (5.49)) and therefore, the term exp(–GD2Δ) vanishes. The same 
approach applied to D2 cannot be applied to D1 and the first term in Eq. (5.58) must be 
considered in detail. By completing the square to match the non-square root component of 
Eq. (5.48), D1 can be rewritten as 
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b f b f b f
f b b f f b
DD
D D D D D D D
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 
                       
       
  (5.64) 
 
73 
 
Since, the typical diffusion values are of the order of magnitude of 10
-9
 m
2
s
-1
, 4 b fD D  can be 
neglected. Therefore, 
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
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

 
 
.  (5.65) 
 
Noting that to first order 121 1x x   , Eq. (5.65) becomes, 
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b b f f
b f
b f
b f
D D
G
D
D D
G
 
 
 


  
     
   
.  (5.66) 
 
The sum of Db and Df  in the denominator is very small compared to the other term and 
therefore can be neglected. Eq. (5.66) then simplifies to, 
 
 
1
1 1
f
f
b b
f f
b b
D
D
D


 
 
 
 
.  (5.67) 
 
By considering the ratio of the lifetimes of the two states relative to the ratio of the 
populations of the two states (see Eq. (5.14)), it can be seen 
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f f
b b
P
P


   (5.68) 
which yields  
 
1
b b f f
f b
D P D P
D
P P



 . (5.69) 
Recalling Eq. (5.10), D1 simplifies to 
 
 1 .b b f fD D P D P    (5.70) 
Thus, E for the fast exchange limit becomes, 
 
  21 exp (2 ) ( )b b f fE P q D P D P      (5.71) 
 
To use Eq. (5.26), the exchanging system must be in fast exchange relative to the 
measurement timescale. As the primary concern is with events on the timescale of Δ in 
diffusion measurements of an exchanging system, a cogent choice of Δ allows the switch 
between slow and fast exchange. 
As an example to the application of Eq. (5.70), the simple and commonly used 
intermolecular exchange model of a ligand (L) exchangeably binding with a macromolecule 
receptor (P), forming a complex (LP) with n identical independent ligand binding sites is 
considered. The system at equilibrium is described by 
 
 
1
1
k
k
L P LP

   (5.72) 
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where the forward rate constant, k+1 (M
-1
s
-1
), favours the binding of the protein and ligand 
molecules and the reverse rate constant k-1 (s
-1
), favours the separation of the protein and 
ligand. Hence, the dissociation constant of the complex, Kd (M), is defined by, 
  
 
1
1
[ ][ ]
.
[ ]
d
kL P
K
LP k


    (5.73) 
 
The lifetimes of the ligand molecule in the free (f) and bound (b) states can be related to the 
forward and reverse rate constants by  
 
 
1 1
1 1
 and .
[ ]
f b
k P k
 
 
    (5.74) 
 
The fractional ligand populations in the free and bounds states are given by 
  
 
[ ]
f
L
L
P
C
   (5.75) 
and  
 
[ ]
b
L
LP
P
C
   (5.76) 
 
where [L] is the concentration of the free ligand, [LP] is the concentration of the bound ligand 
and CL is the total ligand concentration.  
To use this model in the analysis of diffusion NMR experiments, it is necessary to 
express Pb in terms of CL, the total protein concentration, CP, n and K. As each protein 
molecule can bind n ligand molecules, 
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 [ ] [ ]PnC P LP  .  (5.77) 
 
The total ligand concentration is the sum of the free ligand concentration and the ligand 
concentration of the bound complex, 
 
 [ ] [ ]LC L LP  . (5.78) 
 
 
[LP] needs to be obtained in terms of CL, CP and Kd, and thus rearranging Eq. (5.77) yields  
 
 [ ] [ ].PLP nC P    (5.79) 
 
Substituting [P] and [L] from Eqs. (5.73) and (5.78), respectively, 
 
 
[ ]
[ ] .
[ ]
d
P
L
K LP
LP nC
C LP
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
  (5.80) 
 
Rearranging Eq. (5.80) to form a quadratic equation yields 
 
 
2[ ] ( )[ ] 0.L P d P LLP C nC K LP nC C       (5.81) 
 
This can then be solved for [LP] giving,  
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L P d L P d P LC nC K C nC K nC C
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     
  . (5.82) 
 
Substitution of Eq. (5.82) into Eq. (5.76) yields, 
 
 
2( ) ( ) 4
2
L P d L P d P L
b
L
C nC K C nC K nC C
P
C
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 ,  (5.83) 
or more concisely, 
 2
bP       , (5.84) 
 
where 
 
 and .
2
L P d P
L L
C nC K nC
C C
 
 
   By substituting Eq. (5.83) into Eq. (5.70), it is 
possible to quantitatively characterise binding interactions via n and K using the measured 
diffusion coefficient (e.g., refs.[83, 84, 169]). 
 Extension to a Three-State Binding Model 5.3.4
The two-site binding model distinguishes two states (e.g. bound and free) during equilibrium 
binding interactions. However, in some cases, it is unrealistic to define only two states and a 
third state may be applicable. Such cases arise when structural distortions caused by covalent 
interactions are not fully captured by the two-site/two-state model, or multiple binding sites 
are present (e.g., in albumin). In such cases, it may be appropriate to define an intermediate 
state, in addition to the free and bound states. In the context of protein-ligand binding, an 
intermediate state may serve as one where the ligands bind to a different site relative to those 
defined as bound, with different binding properties (i.e., weak binding relative to those that 
are “bound”), as shown in Figure 34. 
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Figure 34: Schematic showing the three possible independent states where (I) - the ligand is free (free 
state), (II) – the ligand is bound (bound state), and (III) – where the ligand is weakly bound (intermediate 
state). 
 
The presence of a third state expands the two-state model (i.e., Eq. (5.26)) to 
 
 
' '' ' ''( ) (1 )b b b b b b b fD P D P D P P D        (5.85) 
 
where 
' '' and b bP P  are the populations of the bound and intermediate state, respectively, and b  
is the diffusion coefficient difference between the bound and intermediate complexes. If Pb
*
 
is the total population of the bound states (i.e., bound and intermediate states, as the 
intermediate state is still considered a bound state), 
 
* ' ''
b b bP P P    (5.86) 
and ΔD is defined as 
 ,b fD D D     (5.87) 
then Eq. (5.85) can be rewritten as 
 
* '' .b f b bD P D D P       (5.88) 
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 Conclusions 5.4
The routine use of NMR methods to quantitatively determine association/dissociation 
constants of ligand-protein binding has long been established, predominantly due to the non-
invasive nature of NMR. NMR measurements preserve the chemical environment of the 
ligand-protein solution, which is an important aspect of equilibrium measurements. Of these 
methods, NMR diffusion measurements allow binding ligands (which assume the diffusion 
properties of the protein) to be easily differentiated from non-binding molecules by 
significant differences in the diffusion coefficients. From such measurements, the Kärger 
model allows association constants to be determined. 
This chapter provides a comprehensive derivation of the two-site Kärger model for two 
freely diffusing species and considers both the slow and fast exchange limits. The derivation 
of the Kärger model begins by combining the diffusion and exchange equations, ultimately 
leading to the population weighted diffusion equation under fast exchange conditions. This 
equation will be used to analyse the binding interactions discussed in the following chapter.  
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Chapter 6. Binding Interactions of 
Different Hypoxia-Targeting Vectors 
 
 
 
 
 
 
 
 
 
 
 
This chapter contains verbatim passages from:  
Dj Wijesekera, Scott A. Willis, Abhishek Gupta, Allan M. Torres, Gang Zheng, William S. 
Price, NMR diffusion and relaxation studies of 2-nitroimidazole and albumin interactions, 
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 193 (2018) 318-
323.  
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 Introduction 6.1
With the numerous hypoxia-targeting vectors available as discussed in Chapter 1, it becomes 
paramount to determine which holds the most promise to be used as a hypoxia-targeting 
vector prior to developing any pO2 detection methods involving these vectors. A suitable 
model for such determinations can be obtained from drug development processes, where 
early stages usually involve characterising drug interactions with plasma proteins [170-174]. 
Plasma proteins, e.g., serum albumin, provide key physiological functions such as transport 
to externally administered drugs due to its abundance and numerous binding sites (i.e., 
covalent, specific and non-specific) [170, 175]. Bovine serum albumin (BSA) is a single-
chain 582 amino acid globular non-glycoprotein cross-linked with 17 cystine residues, with a 
structure similar to human serum albumin (HSA) and is considered an ideal in vitro model for 
studying drug-protein binding [171, 176, 177].  
Drug-protein interactions can be studied using various techniques such as optical 
spectroscopy [178-180], radioactive isotope labelling [181], high performance liquid 
chromatography [182] and NMR [149, 150, 183-187]. Of these, NMR is particularly useful 
since it can provide information on the molecular motion (diffusion) and the local 
environment of the drugs/protein (relaxation). NMR diffusion measurements can probe the 
change in the apparent self-diffusion coefficient of the drug molecule as a function of 
concentration [188]. As the drug molecule binds to the protein, its apparent diffusion 
coefficient decreases due to its interactions with the much larger and more slowly diffusing 
protein molecule. Similarly, NMR relaxation experiments exploit the differences in the free 
and bound relaxation properties of the drug molecule [185]. The relaxation time constants of 
the molecules are dependent on their molecular reorientational motion (and thus, 
reorientational correlation time, τc). For small, fast reorientating molecules (where ω0τc << 1), 
the relaxation time constants decrease with increasing τc [88]. The protein-bound drug 
molecules are expected to relax at a different rate to the unbound, freely diffusing molecules.  
In this chapter, the binding of three hypoxia-targeting vectors to BSA via NMR 
diffusion and relaxation measurements will be investigated. The three hypoxia-targeting 
vectors selected are 2-nitroimidazole, 4-nitroimidazole and 6-nitroquinoline. Where 
applicable, the binding process will be quantified using a two-site binding model for both 
diffusion and relaxation measurements. The different protein concentrations studied are in 
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accordance to a previous NMR binding study [189], with variable hypoxia-targeting vector 
concentrations. 
 Experimental 6.2
  Materials 6.2.1
BSA (heat shock fraction, pH 7, ≥ 98%), 2-nitroimidazole (98%), 4-nitroimidazole (97%) and 
6-nitroquinoline (98%) were purchased from Sigma-Aldrich (Australia). Deuterium oxide 
(D2O) (99.8% D) and sodium deuteroxide (99.5% D, 40% in D2O) were purchased from 
Cambridge Isotope Laboratories Inc (USA). NMR tubes (5 mm, 535-PP-7) were purchased 
from Wilmad LabGlass (USA).  
  Sample Preparation 6.2.2
Stock solutions of 2-nitroimidazole and 4-nitroimidazole in D2O of 0.3 M were adjusted to 
pH ≈ 9.4 and 10.9, respectively using dilute NaOD solution. A 0.3 M stock solution of 6-
nitroquinoline in dimethylformamide (DMF) was also prepared. The stock solutions were 
further diluted to prepare samples for each vector (i.e., 2-nitroimidazole, 4-nitroimidazole and 
6-nitroquinoline) of concentrations ranging from 0.001 - 0.16 M, with protein concentrations 
of 0.23, 0.30 or 0.38 mM. The protein and drug concentrations were based on an earlier study 
investigating the binding of a similar drug and protein molecule [190].   
  NMR Measurements 6.2.3
All NMR experiments were performed on a Bruker Avance III 500 MHz spectrometer 
(Bruker Biospin, Germany) using a 5 mm PABBI-Z inverse probe at 298 K (This temperature 
was chosen to facilitate comparison with an earlier study investigating protein-ligand binding 
by NMR [191]). The calibrated maximum gradient amplitude along the z-axis was 53.5 G 
cm
-1
. Diffusion measurements were obtained using a PGSTE sequence [192], with a diffusion 
time (Δ) of 70 ms and gradient pulse durations (δ) of 1.5 ms. Twenty gradient strengths, 
ranging from 0.11 to 50.93 G cm
-1
 in increments of 2.68 G cm
-1
, were used and each 
spectrum was acquired with 8 scans. Longitudinal and transverse relaxation decay constants, 
T1 and T2, respectively, were obtained using the inversion recovery [72] and CPMG 
sequences [74, 75], respectively. The signal from the inversion recovery pulse sequence (π – 
τ – π/2 – acquire) was acquired for 16 different values of time, τ while the CPMG sequence 
(π/2 – [τ/2 – π – τ/2]n – acquire) was acquired for 16 different values of n, with τCPMG fixed to 
3 ms.  The signal was averaged over 4 scans for T1 and T2, with the recycle delay set to ≥ 5T1. 
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  Data Fitting 6.2.4
All data fitting was performed using OriginPro 9.1 (OriginLab, USA). Diffusion coefficients, 
D, were determined by regressing the equation [76, 90, 193, 194] 
  exp OffE C bD E   ,  (6.1) 
onto the PGSTE attenuation data. In this equation, E is the attenuation of the echo signal. 
 
2
3
b g


 
   
 
 , where γ and g are the gyromagnetic ratio and gradient pulse amplitude, 
respectively. Eq. (6.1) includes a floating amplitude, C, and baseline offset, Eoff to 
accommodate for the slow diffusing protein component, whose signal shows little attenuation 
for the b values used [193, 194]. Likewise, to accommodate for the differently relaxing 
species, biexponential fits, Eqs. (6.2) and (6.3), were used for analysing the relaxation 
measurements, 
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  (6.3) 
where Mz and Mxy represent the longitudinal and transverse magnetisation at times τ or n × 
τCPMG, respectively, M
eq
 is the equilibrium magnetisation, and T1 and T2 are the relaxation 
decay constants of the two components, A and B. A and B refers to the vector and BSA, 
respectively. a1 is 
eq eq
zA zBM M , a2 is 2
eq
zAM  and a3 is 2
eq
zBM .       
The two-site Kärger model [151, 152, 167, 181] was simultaneously fit (i.e., global 
fit) to all NMR measurements (D, T1 and T2) to determine the number of binding sites, n and 
the association constant, K. Eqs. (6.4) and (6.5) were used for diffusion and relaxation 
measurements, respectively,  
     2 21b fD D D              (6.4) 
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     2 21b fR R R              (6.5) 
where  
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2
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C nC
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
 
   (6.6) 
and  
 
BSA
vector
nC
C
   . (6.7) 
R denotes the relaxation rate (where b and f represent the bound and free states). Cvector and 
CBSA are the concentrations of the vector and BSA, respectively. 
 Results and Discussion 6.3
 2-nitroimidazole 6.3.1
As the hydrogen from the amine of 2-nitroimidazole exchanges with the deuterium in 
solution and is not visible in the 
1
H spectra, the 2-nitroimidazole NMR spectrum (Figure 35) 
gives a single 
1
H signal at 7.25 ppm. In this study, it is important to note the slight overlap in 
the 
1
H
 
spectra between the 2-nitroimidazole and BSA peaks as shown in Figure 35. To 
account for this overlap, the diffusion data was analysed with a monoexponential fit with an 
offset (Eq. (6.1)), and the relaxation data was analysed using biexponential fits (Eqs. 
(6.2) and (6.3)). It should be noted that the relaxation of BSA was fixed for the biexponential 
fits of the 2-nitroimidazole T1
 
data. However, the contribution (i.e., signal fraction) of the 
BSA component was negligible in T1 measurements as the corresponding ai term, where i = 2 
or 3, in Eq. (6.2) was approximately zero. 
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Figure 35: 
1
H NMR spectra of 0.005 M 2-nitroimidazole and 0.38 mM BSA solution in D2O. Left Inset: 
Magnified view showing the effect of BSA on the baseline of the spectrum. Right Inset: 
1
H NMR spectrum 
of 0.005 M 2-nitroimidazole (and molecular structure) in D2O between 6.6 – 8.0 ppm. The region from 7.0 
– 7.5 ppm was integrated for all diffusion and relaxation measurements.  
 
The attenuation of the 2-nitroimidazole signal was a single exponential in all cases, 
indicating that the 2-nitroimidazole was in fast exchange between the free and bound states 
on the time-scale of Δ [167, 195]. According to the two-site binding model for first-order 
reversible fast exchange [196-198], the observed diffusion coefficient, D, is the population 
weighted average of the bound and free diffusion coefficients Db and Df, respectively via  
 b b f fD P D P D    (6.8) 
where the populations of bound (Pb) and free (Pf) states are; 
 1 .f bP P    (6.9) 
Assuming that the 2-nitroimidazole takes the diffusion coefficient of BSA when it’s 
bound, the data in Figure 36 shows a greater proportion of 2-nitroimidazole in the bound state 
at low concentrations of the drug (i.e., higher relative BSA concentration shifts the binding 
equilibrium towards more bound 2-nitroimidazole). In addition, the increase in diffusion with 
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decreasing BSA concentration further confirms the binding of 2-nitroimidazole to BSA. As 
there is neither a change in the chemical shift of 2-nitroimidazole nor a loss of its NMR 
signal, it is unlikely that any form of chemical binding is occurring. The diffusion coefficient 
of the solvent (i.e., HDO in D2O) was calculated to be ≈ 1.9 × 10
-9
 m
2
s
-1
 for all three protein 
concentrations at 0.16 M 2-nitroimidazole concentration, verifying any changes in the 
solution viscosity due to different protein concentrations, to be negligible. Furthermore, the 
protein spectra did not show any linewidth changes with increasing protein concentration. 
This suggests that the data was not influenced by protein aggregation. Therefore, surface 
binding through inter-molecular forces such as van der Waals and hydrogen bonding forces 
are likely to be driving the binding processes of this system [199].    
 
Figure 36: Diffusion coefficients of 2-nitroimidazole in BSA solutions at 298 K with BSA concentrations 
of 0.23 (), 0.3 () and 0.38 () mM. 
 
The spin-lattice relaxation rate (R1) and spin-spin relaxation rate (R2) were also 
measured as shown in Figure 37. Applying a two-site binding model to the relaxation 
measurements, Eq. (6.5), the observed relaxation rates, R1 and R2 are the weighted average of 
the respective relaxation rates in the bound and free states. Similar to the diffusion 
measurements, a greater proportion of the 2-nitroimidazole molecules are expected to be 
found in the bound state at lower concentrations of the drug than at higher concentrations. 
Hence, the relaxation time should increase with increasing 2-nitroimidazole concentration, 
resulting in a corresponding decrease in the relaxation rate. This was observed in the present 
study, as shown in Figure 37.  
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Figure 37: Relaxation measurements of 2-nitroimidazole in BSA solutions at 298 K with BSA 
concentrations of 0.23 (), 0.3 () and 0.38 () mM. Error bars for most data points lie within the 
symbol. 
 
The binding model, Eq. (6.4) and (6.5), was simultaneously fit to all the datasets (i.e., 
D, R1 and R2 for all three protein concentrations and all 2-nitroimidazole concentrations) 
using the Levenberg Marquardt algorithm [193]. The protein concentrations were fixed. The 
diffusion of 0.23, 0.30 and 0.38 mM BSA (i.e., Db) was determined to be (8.36 ± 0.28), (5.53 
± 0.11) and (4.78 ± 0.04) × 10
-11
 m
2
s
-1
, respectively. The diffusion and relaxation of 2-
nitroimidazole in the absence of BSA was measured as a function of 2-nitroimidazole 
concentration and the results were interpolated with a second-order polynomial. In the case of 
relaxation, R1f and R2f denote the spin-lattice and spin-spin relaxation rates in the free state, 
respectively. The adjusted R-squared values of the second-order polynomials describing Df, 
R1f and R2f were 0.93, 0.95 and 0.86, respectively. It is noted that seven 2-nitroimidazole 
concentrations were used to determine the second-order polynomial for R2f, as one data point 
was deemed to be an outlier. The parameters, n and K were shared across all data sets. The 
number of binding sites was calculated to be 21 ± 3 and the association constant 53 ± 4 M
-1
. 
The other calculated parameters, R1b and R2b, which represent the calculated relaxation 
measurements for 2-nitroimidazole in the bound state, are tabulated in Table 1. However, 
these results may suffer from imprecision. In the case of the relaxation measurements, the 
bound parameters (Rb) were estimated as these could not be measured directly. These 
parameters are strongly correlated to K, hence a small change in the relaxation of the bound 
values could cause a significant change to the calculated parameters of the model.   
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Table 1: Fitted bound state parameters for 2-nitroimidazole in BSA solutions at 298 K for different BSA 
concentrations where n = 21 ± 3 and K = 53 ± 4 M
-1
. The parameters were obtained from analysis of the 
data over the 2-nitroimidazole concentration range of 0.005 – 0.16 M.  
BSA (mM) R1b (s
-1
) R2b (s
-1
) 
0.23 4.31 ± 0.57 28.68 ± 3.69 
0.30 3.62 ± 0.49 29.19 ± 3.67 
0.38 3.18 ± 0.45 31.25 ± 3.92 
 
The fitted models for each data set are shown in Figure 38. The relaxation data 
appears to be more accurate for describing this system. This could be partly due to the 
increased signal-to-noise ratio for relaxation spectra compared to diffusion spectra, where the 
pulsed field gradients significantly reduce the signal intensity. However, care should be taken 
when interpreting relaxation measurements for molecules with different functional groups. 
This is because local molecular rotation and site dependency can complicate relaxation data, 
conducing to different relaxation rates for different peaks of the same molecule [181]. In 
contrast, the diffusion coefficient is a molecular property where different NMR peaks of a 
molecule describe the motion of the same molecule [181]; hence diffusion measurements can 
be more easily interpreted. 
The NMR-based determinations of n and K in this study are in contrast to those 
obtained using other methods [177, 191, 200], where near equivalent protein and ligand 
concentrations were used to observe high-affinity specific binding, obtaining n ≈ 1 or 2. 
Albumin, despite having two main binding sites (Sudlow site I & Sudlow site II) [170], has 
the ability to ‘soak up’ ligands in a non-specific manner via weak affinities. In most cases, the 
interaction between albumin and most small molecules can be described by a single high 
affinity binding site and several non-specific binding sites [191]. NMR determined n and K 
from studies performed at high ligand to protein ratios (as in the current study) tend to be 
more sensitive to low-affinity non-specific binding. The n and K values determined in this 
study were similar to those obtained in other NMR studies for albumin ligand solutions [145, 
191].   
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Figure 38: The two-site binding (Kärger) model fits to A) diffusion, B) R1 and C) R2 datasets with 1) 0.23, 
2) 0.3 and 3) 0.38 mM BSA. The lines indicate the simultaneous fit of the two-site Kärger model to each of 
the datasets, as described in the text. 
 
It should be noted that over-parameterisation of the binding model leads to a reduced 
robustness in the model, and depending on what initial values are used, multiple fits may be 
possible. Simultaneously fitting the data sets was deemed more appropriate than separating 
D, R1 and R2 and fitting those individually. This provided the most robust fit, with an adjusted 
R-squared of 0.99. A prior NMR study of salicylate binding to HSA determined n and K to be 
33 and 62.5 M
-1
 (calculated from the dissociation constant, Kd = 0.016 M using 1 dK K ), 
respectively [181]. An NMR diffusion study of salicylate binding to BSA yielded similar 
results for n and K of 31 ± 2 and 33 ± 4 M (calculated from Kd = 0.030 ± 0.004 M), 
respectively [167]. In both these studies, the samples were at pH 7.4. In the present study, a 
higher pH of 9.4 was used to accommodate for the insolubility of 2-nitroimidazole. It is 
important to note, the use of a higher pH can cause protein to unfold, which may increase the 
number of BSA-ligand interactions [201]. Although NMR spectroscopy revealed no 
significant structural changes to BSA at pH 9.4, the pH and the type of molecule can be 
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expected to change the binding equilibrium as observed in the results of this study. 
Furthermore, unlike the previous studies where each parameter was determined through 
individual fits, the current study fit all three NMR parameters for all BSA and 2-
nitroimidazole concentrations simultaneously. To the best of our knowledge, this is the first 
such study involving a global fit to the data.          
 4-nitroimidazole  6.3.2
The molecular structure, as shown in Figure 39a, reveals three different proton (
1
H) 
environments, thus should be represented as three different chemical shifts in the 
1
H NMR 
spectra. In practice however, the amine of 4-nitroimidazole exchanges with the deuterium in 
solution and is not visible in the spectra, as shown in Figure 39b. Similar to 2-nitroimidazole, 
there is a slight overlap in the 
1
H spectra between the 4-nitroimidazole and BSA peaks 
between 7-8 ppm. Hence the diffusion and relaxation data was analysed as reported 
previously (i.e., as for 2-nitroimidazole).  
 
 
Figure 39: a) Molecular structure of 4-nitroimidazole b) 
1
H NMR spectra of 0.005 M 4-nitroimidazole in 
D2O.  The 
1
H NMR peaks of 4-nitroimidazole are found at 7.37 and 7.96 ppm.  
 
The diffusion coefficients for 0.005, 0.02, 0.05 and 0.16 M 4-nitroimidazole in 0.30 
mM BSA are shown in Figure 40. Assuming that the 4-nitroimidazole takes the diffusion 
coefficient of BSA when its bound, the two-site binding model states that the diffusion 
coefficient of the 4-nitroimidazole will increase with increasing concentration. This is not 
observed in Figure 40, which indicates a lack of binding between 4-nitroimidazole and BSA.  
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Figure 40: Diffusion coefficients of 4-nitroimidazole in 0.3 mM BSA at 298 K. The larger errors at lower 
concentrations are due to low signal-to-noise at these concentrations.  
 
The diffusion coefficients in Figure 40 appear to decrease with increasing concentration. 
However, this is most likely exaggerated by the larger errors at low concentrations. Although, 
it is also possible that the diffusion coefficient decreases slightly with increasing 
concentration, which could be indicative of self-obstruction or aggregation, or both to a very 
small degree [76]. This was further confirmed to be likely by observing the diffusion 
coefficient of 4-nitroimidazole in D2O for the same concentrations.  The results obtained 
were almost identical to the diffusion coefficients obtained in the BSA solution, which 
indicates the behaviour of 4-nitroimidazole is no different in D2O or BSA.  
The relaxation measurements of 4-nitroimidazole in BSA are shown in Figure 41. R1f 
of 4-nitroimidazole at peaks 7.96 and 7.37 ppm were estimated to approach 0.07 and 0.08, 
respectively with increasing 4-nitroimidazole concentration across the range of 0.005 – 
0.16 M. R2f of 4-nitroimidazole at peaks 7.96 and 7.37 ppm were estimated to approach 0.54 
and 1.57 s
1
, respectively. It is interesting to note that the R1 and R2 values of 4-nitroimidazole 
in BSA with increasing 4-nitroimidazole concentration approach R1f and R2f of 4-
nitroimidazole, which would be indicative of binding according to the two-site model. 
Therefore, it is unclear why a similar trend was not seen with the diffusion data, and this is 
discussed below. With the diffusion data indicating no binding was occurring, and the global 
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fit in the previous section requiring all three datasets (diffusion, R1 and R2), no further protein 
concentrations were investigated for 4-nitroimidazole and no quantitative binding analysis 
was undertaken. 
The contradicting trends between the diffusion and relaxation data are most likely due 
to the different time scales that these two methods (i.e., relaxation and pulsed-field gradient 
(PFG) NMR) report on. Generally, in experiments involving the solution state, relaxation 
measurements are sensitive to motions occurring in the picosecond to nanosecond time scale 
(i.e., motion on the time scale of the reorientational correlation of the nucleus), while in PFG 
measurements, motion is measured over the millisecond to second time scale [164]. Hence, it 
is possible that the binding interactions between BSA and 4-nitroimidazole are considerably 
weak, thus exchanging significantly quickly, such that it is not detected by PFG 
measurements (i.e., diffusion measurements).  
 
 
Figure 41: a) Spin-lattice and b) spin-spin relaxation rates of 4-nitroimidazole in 0.3 mM BSA at 298 K. 
Errors bars of most data points lie within the symbol. 
 
 6-nitroquinoline 6.3.3
The molecular structure of 6-nitroquinoline, as shown in Figure 42a reveals six different 
proton (
1
H) environments, and is represented as six different chemical shifts in the 
1
H NMR 
spectra (Figure 42b). Dissimilar to 2-nitroimidazole and 4-nitroimdazole, the peaks of 6-
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nitroquinoline are present beyond 8 ppm, which eliminates any significant overlap with the 
BSA peaks. Hence the diffusion, T1 and T2 data were analysed with monoexponential fits; 
  expE C bD    (6.10) 
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respectively. 
 
 
Figure 42: a) Molecular structure of 6-nitroquinoline b) 
1
H NMR spectra of 0.16 M 6-nitroquinoline in 
D2O and dimethylformamide (DMF).  The 
1
H NMR peaks of 6-nitroquinoline are found at 9.67, 9.54, 
9.27, 9.03, 8.80 and 8.33 ppm. The D2O peak is at 4.79 ppm, and the DMF peaks are at 3.31 (CH3), 3.47 
(CH3) and 8.53 (CH) [202].   
 
The diffusion coefficients of 6-nitroquinoline concentrations ranging from 0.001 to 
0.16 M in 0.30 mM BSA are shown in Figure 43. The diffusion coefficients obtained by 
analysing the six peaks of 6-nitroquinoline do not conform to the trend indicative of 6-
nitroquinoline binding to BSA. If the errors are considered, the diffusion coefficients either 
remain consistent across the defined concentration range, or otherwise, present a slight 
increase with decreasing concentration. If the former is considered, it is possible the diffusion 
coefficients may have plateaued, indicating the sample was saturated at those concentrations. 
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Given the low concentrations of 6-nitroquinoline studied starting at 1 mM, this is unlikely, 
and further lower concentrations cannot be practically investigated due to the time required to 
generate reasonable signal-to-noise (i.e., more scans).  If the latter is considered, this is most 
likely indicative of self-obstruction or aggregation (again to a small degree), which is further 
suggested by the diffusion coefficients of the free 6-nitroquinoline samples (i.e., 6-
nitroquinoline in D2O), where a similar trend was observed with the diffusion coefficients 
approaching 4 × 10
-10 
m
2
s
-1
 with increasing 6-nitroquinoline concentration.  
 
 
Figure 43: Diffusion coefficients of 6-nitroquinoline in 0.3 mM BSA at 298 K obtained from each of the 
six 
1
H spectral peaks at a) 9.67 b) 9.54 c) 9.27 d) 9.03 e) 8.80 and f) 8.33 ppm. 
 
Relaxation measurements of 6-nitroquinoline in BSA are shown in Figure 44 and 
Figure 45. R1f and R2f of 6-nitroquinoline across all six peaks were determined to approach ≈ 
0.3 and 0.4 s
-1
, respectively with increasing 6-nitroquinoline concentration across the range of 
0.001 – 0.16 M. The R1 measurements of 6-nitroquinoline in BSA (and R2 to a lesser extent) 
is indicative of binding, with the relaxation rates decreasing with increasing concentration, 
and approaching R1f and R2f of 6-nitroquinoline. This does not align with the diffusion data 
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(which indicated that 6-nitroquinoline was not binding to BSA), hence for the same reasons 
outlined for 4-nitroimidazole, no further protein concentrations were investigated and no 
quantitative binding analysis was undertaken for 6-nitroquinoline. Furthermore, similar to 4-
nitroimidazole, it is likely that significantly weak binding of 6-nitroquinoline to BSA is 
occurring. However, in this case, it is also possible that the combination of solvents used may 
have contributed to the nature of the binding interactions. The solvent was a mixture of DMF 
and D2O, at a ratio 5:1, respectively, as 6-nitroquinoline is insoluble in water, while BSA is 
insoluble in DMF.    
 
 
Figure 44: Spin-lattice relaxation rates of 6-nitroquinoline in 0.3 mM BSA at 298 K obtained from each of 
the six 
1
H spectral peaks at a) 9.67 b) 9.54 c) 9.27 d) 9.03 e) 8.80 and f) 8.33 ppm. 
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Figure 45: Spin-spin relaxation rates of 6-nitroquinoline in 0.3 mM BSA at 298 K obtained from each of 
the six 
1
H spectral peaks at a) 9.67 b) 9.54 c) 9.27 d) 9.03 e) 8.80 and f) 8.33 ppm. 
 
 Conclusions 6.4
The binding interactions of 2-nitroimidazole, 4-nitroimidazole and 6-nitroquinoline to BSA 
were probed using NMR diffusion and relaxation measurements. Modified diffusion and 
relaxation attenuation equations were used to account for the overlap of the vector and 
protein components in the 
1
H NMR spectra. The 2-nitroimidazole results demonstrated that 
both diffusion and relaxation measurements are suitable for studying such binding 
interactions, however, the relaxations measurements gave better agreement with the two-site 
Kärger model. Simultaneously fitting the data obtained from the NMR measurements (D, R1 
and R2) yielded significantly more robust results than individually fitting each dataset. The 
number of binding sites and the association constant were determined to be 21 ± 3 and 53 ± 4 
M
-1
, respectively, for 2-nitroimidazole and BSA at 298 K and pH 9.4. It is likely the binding 
interactions between BSA and the vectors, 4-nitroimidazole and 6-nitroquinoline were 
considerably weak, and therefore not detected by PFG NMR. Hence the number of binding 
sites and the association constant were not determined for these vectors. As such, 2-
nitroimidazole was determined to be the most favourable vector (i.e., the most likely to be the 
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strongest binding) of the three studied in this chapter, hence will be the vector used in the 
synthesis in the following chapter.      
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Chapter 7. Synthesis of Paramagnetic 
Liposomes 
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 Introduction 7.1
Liposomes are well established drug delivery systems as they are biocompatible (due to being 
composed of phospholipids), have the ability to accommodate both hydrophilic (in the 
aqueous core) and hydrophobic (in the bilayer membrane) drugs, and are passively targeted to 
tumors due to the enhanced permeation and retention effect [143, 203]. As mentioned 
previously in Chapter 4, liposomes also possess favourable properties to be used as MRI 
contrast agents. For example, liposomes incorporating amphiphilic Gd-chelates are known to 
possess much better contrast enhancement efficiency (i.e., relaxivity) than small molecular 
Gd-chelates [204]. Such paramagnetic liposomes can also provide a large payload of Gd ions 
to a localised area, especially if they are actively targeted via the incorporation of targeting 
vectors. By incorporating hypoxia-targeting vectors and amphiphilic Gd-chelates within the 
bilayer membrane of the liposome, it presents the opportunity to develop hypoxia-targeting 
self-assembled amphiphilic paramagnetic/contrast agents. 
The characterisation of a contrast agent, especially paramagnetic ions and 
superparamagnetic particles used as contrast agents in MRI, usually involves examining 
relaxivity. This is important as contrast agents tend to behave differently at different magnetic 
field strengths, and such characterisations aid in determining the potential suitability of new 
contrast agents for clinical applications, as clinics tend to utilise relatively low magnetic 
fields of approximately 1-3 T. Whilst relaxivity can be observed at specific magnetic fields as 
described in Chapter 4, relaxivity can also be measured as a function of magnetic field 
strength using a method referred to as relaxometry. The data curves obtained from 
relaxometry are known as NMRD profiles. 
In this chapter, the synthesis of liposomal paramagnetic agents, incorporating 2-
nitroimidazole for hypoxic targeting, and amphiphilic Gd-chelates for contrast enhancement, 
into the lipid bilayer, will be presented. These agents were characterised using dynamic light 
scattering (DLS) and inductively coupled plasma mass spectrometry (ICP-MS). The 
relaxivities of the paramagnetic agents with respect to composition and magnetic field 
strength are also reported.     
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 Materials and Methods 7.2
 Materials 7.2.1
2-nitroimidazole (98%), 1-bromooctadecane (97%) and all other chemicals were purchased 
from Sigma-Aldrich (Australia). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(PEG2000 PE), cholesterol, Gd-DTPA-bis(stearylamide) (Gd-DTPA-BSA) were purchased 
from Avanti Polar Lipids (USA). All solvents were purchased from Chem Supply (Australia).  
 Synthesis of (2-nitroimidazoyl)octadecane 7.2.2
The 2-nitroimidazole lipid component, (2-nitroimidazoyl)octadecane was synthesised 
according to a previously reported procedure [205] with minor modifications, as summarised 
in Scheme 1 and discussed below. 
2-Nitroimidazole (0.27 g, 2.4 mmol) and 1-bromooctadecane (1.02 g, 3.05 mmol) 
were suspended in acetonitrile (20 mL) in the presence of excess potassium carbonate (2 g) 
and heated at 70 °C for five days. The solvent was evaporated under vacuum and the residue 
redissolved in dichloromethane (DCM). The base was then filtered and the filtrate purified 
over silica using DCM/methanol (with methanol varying from 0 – 5%) as eluent. The pure 
fractions (determined by TLC using 95/5 DCM/methanol) were combined and the solvents 
evaporated under vacuum to obtain 0.7 g (80%) of pure 1-(2-nitroimidazoyl)octadecane as a 
white powder.  
1
H NMR (400 MHz, CDCl3): 7.14 ppm (d, 1H, Ar), 7.07 ppm (d, 1H, Ar), 4.40 ppm 
(t, 2H, CH2– Nring), 1.84 ppm (m, 2H, CH2–CH2–Nring), 1.36 – 1.22 ppm (m, 30H, CH3–
(CH2)15–CH2–CH2–Nring), 0.88 ppm (t, 3H, CH3–(CH2)15–CH2–CH2–Nring). 
 Liposome Preparation 7.2.3
Two sets of liposomes (Sets A and B) were prepared with each set divided into two types 
(Type I and II). Molar lipid compositions of DPPC:PEG2000PE:cholesterol:Gd-DTPA-
BSA:(2-nitroimidazoyl)octadecane for Set A, Type I and II, respectively were 35:5:30:20:10 
and 45:5:30:20:0, and Set B, Type I and II, respectively were 35:0:30:25:10 and 
45:0:30:25:0. The total lipid concentration was 50 mM. Liposomes were prepared using the 
thin lipid film hydration method [206]. Lipids were first dissolved in chloroform/methanol 
and mixed thoroughly. Solvents were slowly dried under reduced pressure to form a thin lipid 
film, which was lyophilised overnight. The lipid film was rehydrated with PBS solution at 60 
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°C and vortexed for ~2 h. The samples were then extruded 12 times (at approximately 60 °C) 
through a 200 nm polycarbonate filter, followed by 12 extrusions through a 100 nm 
polycarbonate filter (Whatman, GE Healthcare, UK) using a mini-extruder (Avanti Polar 
Lipids, USA). The size of the liposomes was measured by DLS (Malvern Zetasizer μV, UK). 
 Dynamic Light Scattering 7.2.4
For DLS measurements, the liposomes were diluted to approximately 100 μM (lipid 
concentration) in PBS.  The samples were equilibrated for 3 min. Each sample was run three 
times, with each run obtaining 15 measurements of 10 s duration each (i.e., one 
measurement). The average of the three runs was taken as the final result.  
 Relaxivity Studies 7.2.5
Four dilutions were prepared of each liposome formulation by adding Milli-Q water. NMR 
relaxation time measurements of the dilutions were measured at 25 °C on two spectrometers: 
a Magritek Spinsolve 43 MHz (1 T) benchtop spectrometer (Magritek, New Zealand) and a 
Bruker Avance 500 MHz (11.7 T) spectrometer (Bruker Biospin Corporation, Germany). T1 
measurements were performed using the inversion recovery method [72]. Samples were 
placed in straight capillary tubes (529-D, Wilmad LabGlass, USA) in 5-mm NMR tubes 
(528-PP-7, Wilmad Lab Glass, USA) and were equilibrated for 10 min at the set temperature 
prior to conducting the measurements. The recycle delay was set to ≥ 5 T1 with the signal 
averaged over four scans. All data fitting for T1 was performed using OriginPro 2018 
(OriginLab, USA). The relaxivity was calculated from the slope of either the inverse 
relaxation time versus Gd concentration (determined by ICP-MS), or the inverse relaxation 
time versus relative chemical shifts [207]. 
The 
1
H NMRD profiles were obtained at 25 °C using a Spinmaster Fast Field Cycling 
(FFC)-2000 NMR relaxometer (Stelar, Mede PV, Italy) over a continuum of magnetic fields 
from 2.35 × 10
-4
 to 0.94 T, corresponding to a 
1
H Larmor frequency range of 0.01 – 40 MHz. 
The dead time of the spectrometer was approximately 10 µs.  
 Inductively-Coupled Plasma Mass Spectrometry 7.2.6
Concentrated nitric acid (Sigma-Aldrich, Australia) was added to the liposomal formulations 
in glass vials (4 ml) and left to digest over 2 days. The samples were then heated to 180 °C on 
a SPB 15-108 heating block (PerkinElmer, USA) for ≈ 4 h to complete the digestion and acid 
evaporation. Nitric acid (3% w/w, 3 ml) was added to resuspend the remaining sample (such 
that a 1 in 4000 dilution of the original liposomal solution was obtained), prior to transferring 
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samples into Falcon tubes (15 ml). ICP-MS of Gd concentrations was performed using a 
NexION 300X ICP-MS instrument (PerkinElmer, USA). 
 Results and Discussion 7.3
 Synthesis of (2-nitroimidazoyl)octadecane 7.3.1
1-(2-nitroimidazoyl)octadecane was synthesised according to Scheme 1 and as discussed in 
the Methods, to act as an amphiphilic hypoxia-targeting vector. Hypoxia-specific 
paramagnetic liposomes were then formulated by incorporating commercially available 
paramagnetic amphiphilic chelates, and 1-(2-nitroimidazoyl)octadecane lipids within the 
bilayer membranes of the DPPC lipids as further discussed below. 
 
 
Scheme 1: Synthesis scheme of 1-(2-nitroimidazoyl)octadecane (Yield: 80%). 
 
 Liposome Preparation 7.3.2
As the liposomes were prepared as potential MRI contrast agents, a formulation that ensures 
long circulation times was required. The most popular method to obtain longer circulation 
times is to incorporate PEGylated lipids into the liposomal composition. PEG acts as a shield, 
protecting the liposome against interactions with molecular and biological components in the 
blood stream. In contrast, liposomes without PEG have short circulation times due to rapid 
uptake by phagocytic cells of the reticuloendothelial system [208]. 
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In the present case, the 2-nitroimidazole amphiphiles were incorporated within the 
bilayer membrane and not at the distal end of the PEG spacers. As the incorporation of the 
PEGylated lipids had the potential to reduce the hypoxia-targeting ability of the liposomes 
[209-212], two sets of paramagnetic liposomes were formulated. PEGylated lipids were 
incorporated into one set of the liposomal membranes (Set A) but not in the other set (Set B) 
(Figure 46). Cholesterol was added to the liposomes to act as a spacer, and to improve their 
steric stabilisation [213]. The most optimal formulation for long circulation times is known to 
be a high cholesterol concentration of approximately 30% or greater, and a low PEG 
concentrations of 7% or less [206, 214]. As a result, 30% cholesterol was used for both sets 
of liposomes, with 5% PEG for Set A.   
 
 
Figure 46: Schematic representation of the two sets of hypoxia-targeted paramagnetic liposomes 
formulated in this study. Set A liposomes were prepared with PEGylated lipids incorporated within their 
bilayer membrane to increase their in vivo circulation times. Set B liposomes were prepared without any 
PEGylated lipids to assess if there was any increase in the targeting ability of these liposomes in the 
absence of sterically hindering PEG spacers.  
 
The preparation of the liposomes was divided into three stages: preparation of the 
lipid film, hydration of the lipid film and extrusion, as shown in Figure 47. In the first stage, 
the lipids were dissolved in a chloroform:methanol mixture to obtain a clear lipid solution, 
indicating complete mixing of the lipids (Figure 48a). Typically, lipid solutions are prepared 
at 10-20 mg of lipid per millilitre of organic solvent. In this study, approximately 12 mL of 
methanol:chloroform solution (50:50 ratio) was used for approximately 100 mg of lipid to 
ensure complete solubility of all components. The solvent was then removed by rotary 
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evaporation yielding a thin lipid film on the sides of the round bottom flask (Figure 48b), 
after which the lipid film was lyophilised overnight to remove residual organic solvent. 
 
 
Figure 47: The three stages of liposome preparation – 1: The thin lipid film was prepared by dissolving 
the lipid components in an organic solvent, which was then removed using a rotary evaporator (the 
lyophilisation of the film has not been shown in this schematic), 2: 3 mL PBS solution was added to 
hydrate the dry lipid film, resulting in the formation of multilamellar vesicles, and 3: multilamellar 
vesicles were reduced to unilamellar vesicles by passing the solution through an extruder (image adapted 
from ref. [215]).   
 
Hydration of the dry lipid film was accomplished by adding 0.01 M PBS and agitating 
the round bottom flask. The PBS was maintained at 60 °C to ensure the temperature of the 
hydrating medium was kept above the gel-liquid crystal transition temperature (TM) of the 
lipid. The product of hydration is generally large, multilamellar vesicles. The multilamellar 
vesicles were reduced to small, uniform unilamellar vesicles via extrusion (Figure 48c). The 
liposomes were also extruded at 60 °C. At this point, translucent solutions were obtained (i.e., 
the liposomal formulations) (Figure 48d).    
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Figure 48: Images taken during the liposome preparation process showing a) the complete mixing of the 
lipids to obtain a clear lipid solution, b) the yielding of a thin lipid film inside the round bottom flask 
following rotary evaporation, c) the extrusion process, with the extruder maintained at 60 ºC on a hot 
plate and d) the liposomal formulations obtained after extrusion.  
 
 DLS Measurements 7.3.3
The average size and polydispersity index (PDI) for each set and type of liposomes are shown 
in Table 2. On average, all liposomal formulations showed similar sizes (100 – 120 nm). The 
PDIs however, were different for liposomes with and without PEG. The wider size 
distribution of the liposomes without PEG as shown by the PDI and the distribution plots 
(Figure 49) may potentially indicate the instability of these liposomes due to the absence of 
PEG, thus possibly resulting in the aggregation and gravitational settling of the colloidal 
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particles [216]. However, there seemed to be no significant effect of the incorporation of 2-
nitroimidazole amphiphiles on the size or PDI of the liposomes.  
Table 2: The average size (diameter) and PDI of each liposomal formulation. 
 Set A Set B 
 Type I Type II Type I Type II 
Size (nm) 122.8 112.5 103.5 108.9 
PDI 0.2 0.2 0.5 0.5 
 
 
Figure 49: Liposome size distribution plots at 25  ̊C for a) Set A, Type I, b) Set A, Type II, c) Set B, Type I 
and d) Set B, Type II. The average count rate was 295 kilo counts per second (kcps). 
 
 ICP-MS 7.3.4
ICP-MS was then conducted on the samples to determine the exact Gd concentrations prior to 
calculating the relaxivities. The Gd concentration for each liposomal formulation is shown in 
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Table 3. The lower Gd concentration in Set B despite the higher Gd concentration of 25% 
(compared to 20% for Set A) added during the formulation is most likely the result of 
instability of the non-PEG liposomes [216]. Gravitational settling was observed for these 
liposomes following the synthesis, hence it is likely that some precipitation may have 
occurred during the extrusion process, yielding lower Gd concentrations in the liposomes 
without PEG.  
Table 3: Gd concentrations (mM) of liposomes determined by ICP-MS. 
Set A Set B 
Type I Type II Type I Type II 
6.5 7.4 4.3 4.1 
 
 Relaxivity 7.3.5
The relaxivities of the liposomal formulations at 1 and 11.7 T are shown in Table 4 and Table 
5, respectively. In general, the relaxivities at low magnetic fields (i.e., 1 T) were found to be 
higher than that reported for the commonly used commercial contrast agent, Magnevist (r1 
and r2: 3.8 and 4.2, respectively [217]). This is of significance in the clinics which use 
approximately 1-3 T magnets (e.g., [12]). At high magnetic fields (i.e., 11.7 T), r2 was found 
to be significantly higher for all liposomal formulations (Table 5) than Magnevist (r1 and r2: 
3.8 and 4.9, respectively [217]). However, the r1 at high fields for all liposomal formulations 
was lower, at approximately 2 mM
-1
s
-1
. Despite the lower r1 for the liposomal formulations at 
11.74 T (relative to 1 T), it is worthwhile noting the relaxivities are reported in terms of the 
Gd(III) ion concentrations, thus the relaxivity per liposome particle would be significantly 
higher. This is because each liposome contains numerous Gd(III) ions. For example, a 100 
nm liposome with a lipid surface area of 0.6 nm
2
 contains approximately 40,000 Gd(III) ions 
[208, 218]), which would result in a relaxivity in the order of 80,000 per nanoparticle s
-1
.  
The NMRD-profiles of the liposomal formulations are shown in Figure 50. This 
shows higher relaxivities in the 20-40 MHz region, indicating a longer τR of the Gd chelates. 
This was expected due to liposome incorporation.  
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Table 4: The relaxivities of each liposomal formulation at 1 T.  
 Set A Set B 
 Type I Type II Type I Type II 
r1 (mM
-1
s
-1
) 6.98 6.82 9.97 10.26 
r2 (mM
-1
s
-1
) 8.24 8.02 12.14 12.53 
r2/ r1 1.18 1.18 1.22 1.22 
 
Table 5: The relaxivities of each liposomal formulation at 11.7 T. 
 Set A Set B 
 Type I Type II Type I Type II 
r1 (mM
-1
s
-1
) 2.25 2.09 2.14 2.03 
r2 (mM
-1
s
-1
) 16.63 20.41 42.16 39.57 
r2/ r1 7.39 9.77 19.70 19.49 
 
 
Figure 50: 
1
H NMRD profile for each liposomal formulation: Set A – Type I (■), Set A – Type II (●), Set 
B – Type I (▲) and Set B – Type II (▼).  
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As seen in Table 4 and Figure 50, the liposomes without PEG present higher 
relaxivities compared to those containing PEG. This contradicts Bui, who found the inclusion 
of PEG on Gd-lipid nanoparticle surfaces resulted in approximately a 10-fold increase in r1 
relative to non-PEG liposomes [219]. Gløgård also investigated the effect of membrane 
composition on relaxivity, but observed no increase in relaxivity on PEG-modified Gd 
labelled liposomes [220]. To complicate this further, Issa reported a decrease in relaxivity of 
organic nanoparticles coated with PEG [221], where it was speculated that the reduction in 
relaxation rates is due to the increased distance of closest approach for the surrounding 
protons to the magnetic cores of the coated particles. However, as the liposomes of this 
current study contained Gd in the lipid bilayer, it is unlikely that PEG could have caused a 
similar level of shielding that was present in the organic nanoparticles, which were more rigid 
in structure compared to the liposomes of this current study. While the effect of PEG on the 
relaxivity of nanoparticles appears to not be completely clear at present (i.e., by observing the 
results from Bui and Gløgård), it worthwhile also considering the effective loading properties 
of liposomes as reported by Kabalka [137] to explain the results obtained in this thesis, as 
discussed below.  
Kabalka reported the effect of increasing Gd concentration in liposomes on the 
relaxation rate, R1, showing the most effective rate enhancement (i.e., R1) was attained when 
the amphipathic Gd concentration was one-third of the lipid content of the liposome material. 
Theoretically, increasing the Gd concentration should see an increase in R1. However, 
liposomes containing Gd concentrations greater than 33% of the lipid content reported a 
decrease in R1. This indicates the effective loading capacities in liposomes. Hence, with the 
low molar composition of PEG (i.e., 5%), it is likely that the inclusion of PEG in the 
liposomal formulation for this current study had a minimal effect on r1 (as reported by 
Gløgård), and the differences in relaxivity observed between the liposomal formulations with 
and without PEG were an effect of the loading capacities of the liposomes due to the 5% 
difference in Gd concentration.   
Typically, r2/r1 is used to determine whether a contrast agent is classified as a positive 
(i.e., T1) or negative (i.e., T2) contrast agent. In general, an agent with a r2/r1 of approximately 
1-2 is classified as a positive contrast agent, whereas any agent with a r2/r1 greater than 2 is 
classified as a negative contrast agent. Table 4 and Table 5 indicate the liposomes in this 
study are positive contrast agents at low field and negative contrast agents at high field, as 
reported in other studies [222]. It is interesting to note however, an approximate two-fold 
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increase in the r2/r1 at high field between liposomes with PEG and those without. At this 
stage, it is unclear whether this is related to the exclusion of PEG, or the different Gd 
concentrations, or both. 
 Conclusion 7.4
2-nitroimidazole conjugated to a saturated lipid chain was synthesised to be used as an active 
hypoxia-targeting amphiphilic vector. Liposomes were then formulated by incorporating 2-
nitroimidazole lipids and commercially available paramagnetic amphiphiles within the 
bilayer membrane of phosphatidylcholine phospholipids. As the 2-nitroimidazole 
amphiphiles were incorporated within the bilayer membrane and not at the distal end of the 
PEG spacers, the incorporation of the PEGylated lipids also had the potential to reduce the 
hypoxia-targeting ability of the liposomes. As a result, two sets of paramagnetic liposomes 
were formulated: one set with PEGylated lipids and one set without. Size distribution analysis 
revealed the non-PEGylated liposomes to be less stable in comparison to the PEGylated 
liposomes, resulting in possible aggregation and gravitational settling of the colloidal 
particles. The contrast enhancement efficiency of the liposomes was comprehensively 
characterised as a function of magnetic field strength. At low magnetic fields, the relaxivities 
of all liposomal formulations were higher than that reported for the most commonly used 
commercial contrast agent, Magnevist. 
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Chapter 8. Investigating the Hypoxia-
Specificity of the Paramagnetic 
Liposomes 
 
 
 
 
 
 
 
 
This chapter contains verbatim passages from:  
Dj Wijesekera, Abhishek Gupta, Mohammad S. Zaman, Shawan Karan, Scott A. Willis, Gary 
Dennis, William S. Price, Hypoxia-Specific Paramagnetic Liposomes, ChemistryOpen, 2018 
(submitted).   
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 Introduction 8.1
As mentioned earlier in this thesis, the development of chemicals, incorporating hypoxia-
targeting vectors, which specifically accumulate in hypoxic tissue has become of interest in 
developing methods to non-invasively detect tumor hypoxia. Such chemicals can be 
traced/imaged by an imaging modality, thus allowing delineation of hypoxic parts of a tumor. 
Markers for hypoxic tumors has long been realised [223-226], and have been extensively 
exploited in PET imaging [227, 228], but less so in MRI. In 2012, a Gd-based small 
molecular MRI contrast agent conjugated to 2-nitroimidazole was reported to display hypoxia 
specificity in cells and later in Dunning prostate tumors [63, 64]. These results presented an 
opportunity to extend the hypoxia-targeting capability of 2-nitroimidazole to self-assembled 
amphiphilic nanoparticulate systems.  
This chapter reports on the hypoxia-targeting ability of the novel hypoxia-specific 
paramagnetic liposomes synthesised in Chapter 7, which incorporated 2-nitroimidazole 
amphiphiles as hypoxia-targeting vectors and commercially available amphiphilic Gd-
chelates to impart MRI contrast. The hypoxia-specificity of the liposomes will be assessed in 
two different cell lines: SH-SY5Y human neuroblastoma and MCF-7 human breast 
adenocarcinoma. It is hypothesised that the paramagnetic liposomes with 2-nitroimidazole 
amphiphiles will show higher preference towards hypoxic cells in both cell lines compared to 
the paramagnetic liposomes without 2-nitroimidazole amphiphiles. 
 Materials and Methods 8.2
 Materials 8.2.1
SH-SY5Y (human neuroblastoma) and MCF-7 (human breast adenocarcinoma) cells were 
purchased from American Type Culture Collection (ATCC, Australia). Fetal Bovine Serum 
(FBS), L-glutamine, penicillin/streptomycin, trypsin, phosphate buffered saline (PBS), 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM/F12 Hams), 
nitric acid (69%) and all other chemical were purchased from Sigma-Aldrich (Australia). 
 In Vitro Cell Studies 8.2.2
In vitro cell studies were performed using a similar protocol as reported in ref.[63], with 
some modifications, as noted below. 
Cells were cultured in DMEM/F12 Hams supplemented with 10% FBS, 1% 
penicillin/streptomycin and L-glutamine. Approximately 1 × 10
5
 cells were seeded into a 25 
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cm
2
 tissue culture flask (Greiner Bio-One, Germany) with 6 mL complete medium, incubated 
at 37 
o
C with 5% CO2 in a Thermo Scientific HERA 150 (ThermoFisher Scientific, Australia) 
and grown to confluence. The complete medium was replaced with un-supplemented DMEM 
(6 ml) before the uptake experiment. One flask of cells was made hypoxic by passing 
nitrogen through it continuously at 0.8 L/min for 2 h. Air was passed through the two other 
flasks at 0.8 L/min to keep them normoxic (the experimental setup is shown in Figure 51). 
Set A, Type I paramagnetic liposomes (i.e., the liposomes with 2-nitroimidazole amphiphiles) 
were added to the hypoxic and one of the two normoxic flasks with SH-SY5Y cells, yielding 
the total lipid concentration of 6.1 mM (equating to 1.2 mM Gd) in each flask. PBS was 
added as the negative control in the remaining normoxic flask with SH-SY5Y cells. Three 
other SH-SY5Y samples were prepared using the same procedure to assess the cell uptake of 
Set A, Type II paramagnetic liposomes (i.e., the liposomes without 2-nitroimidazole). These 
samples were incubated for 2 h at room temperature (with nitrogen and air exposure as 
detailed previously), rinsed three times with PBS, trypsinised to release the cells and 
centrifuged in 15 mL Falcon tubes (Sigma-Aldrich, Australia) at 189 g for 5 min. Excess 
buffer was removed from the pellets and the samples were transferred into 0.2 mL 
microcentrifuge tubes for final centrifugation at 189 g for another 5 min. 
The same procedure was followed to assess Set B (i.e., repeat study using a different 
cancer cell line); Types I and II paramagnetic liposomes in MCF-7 cell lines, except the total 
lipid concentration in each flask was 6.8 mM (equating to 1.7 mM Gd). 
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Figure 51: a) Schematic and b) image showing the setup used for obtaining hypoxic and normoxic 
conditions within a 25 cm
2
 flask using nitrogen and air, respectively, flowing through a flow meter at a 
rate of 0.8 Lmin
-1
.   
 
 Magnetic Resonance Imaging 8.2.3
All 
1
H MRI was performed on a 600 MHz (14.1 T) wide-bore NMR spectrometer (Avance 
III, Bruker Biospin, Germany). An acrylonitrile butadiene styrene (ABS) holder (Figure 52) 
was printed on a uPrint SE 3D printer (Stratasys, USA) to position the 0.2 mL 
microcentrifuge tubes within the micro-imaging probe. T1-weighted images were acquired 
with TR/TE = 900/5 ms for the SH-SY5Y cells, and TR/TE = 1000/4 ms for the MCF-7 cells.  
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A rapid acquisition with relaxation enhancement sequence with variable repetition time 
(RARE VTR) was used to obtain relaxation (T1 and T2) measurements. The typical image 
size was 256 × 128 pixels with a TE of 7.95 ms and ten different TR ranging from 70 to 7500 
ms. Data acquisition was done using ParaVision 6.0 (Bruker Biospin). Raw data was then 
exported to MATLAB R2016a (MathWorks, Inc., USA) and T1 maps were generated by 
fitting exponential relaxation curves on a voxel-by-voxel basis. The above detailed protocols 
were validated using water samples via NMR spectroscopy. 
 
 
Figure 52: 3D printed 0.2 mL microcentrifuge tube holder designed on SketchUp Make (Version 15.3, 
United States) and printed on a uPrint SE 3D printer, measuring 70 mm in height and 28 mm in 
diameter. a) The lip and body of the holder were printed separately to ensure that the positioning of the 
microcentrifuge tube could be checked prior to inserting into the probe. b) This image shows the holder 
in the form that it was placed into the imaging probe. 
 
 Inductively-Coupled Plasma Mass Spectrometry 8.2.4
Concentrated nitric acid (140 μL, Sigma-Aldrich, Australia) was added to the cell pellets in 
glass vials (4 ml) and left to digest over 2 days. The samples were then heated at 180 °C on a 
SPB 15-108 heating block (PerkinElmer, USA) for ≈ 4 h to complete the digestion and acid 
evaporation. Nitric acid (3% w/w, 3 ml) was added to resuspend the remaining sample, prior 
to transferring into Falcon tubes (15 ml). ICP-MS of Gd concentrations was performed using 
a NexION 300X ICP-MS instrument (PerkinElmer, USA). 
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 Results and Discussion 8.3
 In Vitro Cell Studies 8.3.1
The hypoxia-specificity of the liposomes was assessed by measuring the cellular uptake of 
liposomes (both with and without hypoxia-targeting vectors) in two different cell lines: 
human neuroblastoma SH-SY5Y and human breast cancer MCF-7 cell lines, under normoxic 
and hypoxic conditions. Hypoxia was induced by passing N2 at 0.8 L/min for 2 h at room 
temperature. Liposomes were then added and the cells were incubated for another 2 h under a 
continuous flow of N2. Similar procedure was followed for normoxic cells except air was 
used instead of N2. A negative control was also prepared in which PBS buffer (pH 7.4) was 
added to the cells instead of liposomes. After the incubation period, the cells were washed 
three times with PBS, detached from the flasks and centrifuged before imaging them on a 
14.1 T MRI scanner. 
 Magnetic Resonance Imaging of the Cells 8.3.2
Cellular uptake of the liposomes in SH-SY5Y and MCF-7 cells in hypoxic and normoxic 
conditions were examined by observing the spin-lattice relaxation time (T1) within the cell 
pellet. The T1-weighted images and T1 maps of the SH-SY5Y and MCF-7 cells incubated 
with Type I liposomes (i.e., with 2-nitroimidazole amphiphiles) under normoxic and hypoxic 
conditions are shown in Figure 53a and b, along with the negative control sample incubated 
with PBS alone. The average T1 values of the cell pellets are plotted in Figure 53c. T2-
weighted images and T2 maps of the SH-SY5Y and MCF-7 cells incubated with Type I 
liposomes (i.e., with 2-nitroimidazole amphiphiles) under normoxic and hypoxic conditions 
were also obtained. However, the results indicated negligible differences in the average T2 
values under the different conditions, hence T2 measurements were not investigated further in 
this thesis.  
If the 2-nitroimidazole components of the liposome underwent reduction and became 
trapped in the hypoxic cells, the accumulation of the Type I paramagnetic liposomes should 
have resulted in brighter T1-weighted images as a result of the shortening of the T1 of the 
water. However, as evident in Figure 53, no significant difference was observed in the 
brightness of the T1-weighted images of the normoxic and hypoxic samples. Accordingly, the 
T1 values of the cells in normoxic or hypoxic conditions did not show any statistical 
difference either. These results suggest that even the Type I targeted paramagnetic liposomes 
were either not hypoxia-specific at all, or had limited specificity. 
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To further assess the hypoxia-specificity of the liposomes, the cells were digested 
using concentrated nitric acid, and the samples were then diluted to 3 ml with 3% nitric acid 
(w/w). The Gd content in the dilutions was then measured using ICP-MS. 
 
Figure 53: T1-weighted images (i) and T1 maps (ii) of in vitro MR imaging of SH-SY5Y (a) and MCF-7 (b) 
cells containing hypoxia-specific liposomes (i.e., containing 2-nitroimidazole) in negative control (C), 
normoxic (N) and hypoxic (H) conditions. The T1-weighted images were acquired with the repetition time 
(TR)/echo time (TE) = 900/5 ms for the SH-SY5Y cells, and TR/TE = 1000/4 ms for the MCF-7 cells. T1 
maps were obtained using RAREVTR pulse sequence with TE = 7.95 ms and TR ranging from 70 – 7500 
ms over 10 points. c) Plots of the average T1 values of the cell pellets of the samples shown in (a) and (b). 
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 Gadolinium Determination by ICP-MS 8.3.3
Gd concentrations determined by ICP-MS for the normoxic and hypoxic samples are 
summarised in Table 6 and plotted in Figure 54, for both cell lines. Contrary to the MRI 
results, ICP-MS revealed approximately three times higher Gd concentration in the hypoxic 
SH-SY5Y cells compared to the normoxic counterparts for the Type I paramagnetic 
liposomes with 2-nitroimidazole amphiphiles. Type II paramagnetic liposomes, on the other 
hand, displayed no preference towards hypoxic cells, as similar Gd concentrations were 
measured in both hypoxic and normoxic cells. Similar trends were observed for MCF-7 cell 
lines and Set B liposomes, with about five times higher Gd in the hypoxic cells than 
normoxic for Type I liposomes. Type II liposomes again showed no preference towards 
hypoxic cells.  
The above results confirm the hypoxia-specificity of the targeted Type I paramagnetic 
liposomes in both SH-SY5Y and MCF-7 cell lines. As expected due to the enhanced 
permeation and retention effect [203], paramagnetic liposomes (with or without 2-
nitroimidazole lipids) entered and were retained in both normoxic and hypoxic cells. 
However, the Type I liposomes with 2-nitroimidazole lipids showed a distinct preference 
towards hypoxic than normoxic cells, which was not observed for the Type II liposomes 
without 2-nitroimidazole lipids. In addition, the Set B liposomes without PEGylated lipids 
showed higher hypoxia-specificity than Set A liposomes with PEGylated lipids, albeit in a 
different cell line (MCF-7 instead of SH-SY5Y). This, once again, confirms that the hypoxia-
specificity of the Type I paramagnetic liposomes is because of the 2-nitroimidazole 
amphiphiles, as the specificity increased when 2-nitroimidazole headgroups embedded within 
the bilayer membrane were made more accessible in the absence of the sterically hindering 
PEG spacers.  
The differences in the Gd concentrations of the normoxic cells of both cell lines (e.g., 
162.3 ppb for Set A, Type I in SH-SY5Y, and 45.5 ppb for Set B, Type I in MCF-7 cell lines) 
can most likely be attributed to the cellular properties of different cell lines and cell passages 
resulting in changes to passive diffusion characteristics for different liposomal formulations. 
Note that the cellular uptake experiments were performed on different cell passages for 
different paramagnetic liposome formulations. Therefore, only relative results (i.e., the 
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negative control, normoxic control, and hypoxic samples) for a paramagnetic liposomal 
formulation should be compared. 
Table 6: Gd concentrations (ppb) detected by ICP-MS after the digestions and dilution of SH-SY5Y and 
MCF-7 cell samples incubated with different paramagnetic liposomes.  
 SH-SY5Y MCF-7 
Conditions Type I Type II Type I Type II 
Normoxic 162.3 ± 2.6 27.7 ± 0.9 45.5 ± 1.4 159.8 ± 5.8 
Hypoxic 455.0 ± 2.9 26.4 ± 0.5 229.0 ± 20.5 121.6 ± 5.4 
 
 
Figure 54: Gd concentrations detected by ICP-MS in the normoxic (N) and hypoxic (H) cell samples for 
a) non-specific (Type II) and b) hypoxia-specific (Type I) liposomes. 
 
The uptake of type I liposomes into the SH-SY5Y cells was calculated to be 
approximately 24% and 9% under hypoxic and normoxic conditions, respectively, and 
similarly, 20% and 4% for the MCF-7 cells. It is worthwhile noting that while the absence of 
PEG appears to improve the targeting ability of the liposomes, it also appears to reduce the 
total uptake into the cells. However in this current study, this can only be speculated as this 
may also be the result of different cellular properties of the different cell lines. 
In summary, the ICP-MS results conclusively confirm the hypoxia-specificity of the 
Type I paramagnetic liposomes for both the cell lines. However, this was not reflected in the 
MRI studies of the cell lines. To further explore this, the contrast enhancement efficiencies 
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(or relaxivities) of the paramagnetic liposomes determined in the previous chapter are 
referred to. At 1 T, the in vitro longitudinal relaxivities of Sets A and B of the paramagnetic 
liposomes were measured to be approximately 7 and 10 mM
-1
s
-1
, respectively, which is 
higher than the relaxivities of commercial Gd-based MRI contrast agents (typically between 3 
and 5 mM
-1
s
-1
 at ≤ 1 T) [65], and in agreement with the values previously reported for similar 
paramagnetic liposomes [204]. The relaxivities were, however, found to be much lower (~ 
2 mM
-1
s
-1
 for both sets of liposomes) at high magnetic field strength. Compared to a previous 
study on the 2-nitroimidazole conjugated Gd complex, which observed a 2-fold reduction in 
the T1 values of the hypoxic cells than normoxic cells [63], cells in this study were incubated 
with a lower total Gd concentration (1.7 mM instead of 5 mM), and MRI studies were 
performed at a much higher magnetic field strength (14.1 T instead of 4.7 T). Both of these 
factors, suggest that even with the hypoxia-specificity of the paramagnetic liposomes, as 
confirmed by ICP-MS, the difference between the T1 values of the hypoxic and normoxic 
cells would likely be lower than the precision of the T1 values measured by MRI. 
 Conclusion 8.4
The hypoxia-targeting ability of the liposomes was assessed by comparing the cellular uptake 
of targeted and non-targeted paramagnetic liposomes in two cell lines: SH-SY5Y human 
neuroblastoma and MCF-7 human breast adenocarcinoma, in normoxic and hypoxic 
conditions. ICP-MS studies revealed a three and five-fold increase in the Gd concentration of 
the hypoxic cells relative to the normoxic cells in the SH-SY5Y and MCF-7 cell lines, 
respectively, confirming the hypoxia-targeting ability of these liposomal formulations. 
Indistinct contrast difference was observed, on the other hand, between the MR images of the 
normoxic and hypoxic cells in either cell-line, thus suggesting the need to design liposomal 
formulations with either higher Gd content, or better contrast enhancement efficiency, or 
both. 
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Chapter 9. General Conclusions and Future 
Work 
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 General Conclusions 9.1
In this thesis, the primary aims of investigating the binding properties of different hypoxia-
targeting vectors, and then synthesising a hypoxia-specific paramagnetic agent using one of 
the studied vectors were accomplished. In doing so, the following objectives were achieved: 
(i) understand and derive the two-site binding Kärger model 
The biological activity of drugs at the molecular level corresponds to the binding of 
small molecules to macromolecular receptors. NMR diffusion measurements allow 
bound molecules to be easily differentiated from unbound molecules. The mathematical 
framework for analysing such data is provided by the Kärger equations. To understand 
the limitations of these equations and the conditions under which they are valid, a 
detailed derivation of these equations for the case of two freely diffusing exchanging 
species was presented in this thesis along with the simplifications that result in the slow 
and fast exchange limits. The derivation concluded at the population weighted diffusion 
equation under fast exchange, which is then used to quantitatively analyse the binding 
interactions of the hypoxia-targeting vectors in Chapter 6 of this thesis.  
 
(ii) quantitatively characterise the binding of different hypoxia-targeting vectors using the 
Kärger model 
With the numerous hypoxia-targeting vectors available as discussed in this thesis, it 
became paramount to determine which holds the most promise to be used as a hypoxia-
targeting vector prior to developing any pO2 detection methods involving these vectors. 
A suitable model for such determination involves characterising the vectors with 
plasma proteins. Hence, the binding of three hypoxia-targeting vectors (2-
nitroimidazole, 4-nitroimidazole and 6-nitroquinoline) to BSA was investigated. A 
thorough understanding of the Kärger equations allowed the weighted diffusion 
equation under fast exchange to be extended to relaxation, thus allowing the binding 
interactions to be investigated via diffusion and relaxation measurements. Observing 
the binding interactions of 2-nitroimidazole and BSA revealed that simultaneously 
fitting the Kärger model to the NMR data (D, R1 and R2) yielded significantly more 
robust results than individually fitting each dataset. The number of binding sites and the 
association constant for 2-nitroimidazole were determined to be 21 ± 3 and 53 ± 4 M
-1
, 
respectively, at 298 K and pH 9.4. Such analysis was not undertaken for 4-
nitroimidazole and 6-nitroquinoline as the binding interactions were considered to be 
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significantly weak. Hence, of the three vectors studied, 2-nitroimidazole was most 
likely to be the strongest binding vector.   
 
(iii) design, synthesise and characterise hypoxia-specific paramagnetic supramolecular 
nanoparticles/agents, which incorporate paramagnetic MRI contrast agent and active 
hypoxia-targeting vectors 
For the reasons of the biocompatibility, synthesis simplicity, high relaxivity properties 
and targeting capabilities, supramolecular aggregates in the form of liposomes were 
selected as the structure of choice to be used in the development of the hypoxia-specific 
paramagnetic agents in this thesis. As 2-nitroimidazole presented the most favourable 
binding properties of the vectors studied, a 2-nitroimidazole conjugated saturated lipid 
chain was synthesised to be used as an active hypoxia-targeting amphiphilic vector. 
Liposomes were then formulated with 2-nitroimidazole lipids and paramagnetic 
amphiphiles incorporated within the bilayer membrane of phosphatidylcholine 
phospholipids. Size distribution analysis revealed the liposomes to be uniform in size 
(approximately 100-120 nm in diameter). Characterising the contrast enhancement 
efficiency of the liposomes revealed the relaxivities for all liposomal formulations in 
this study to be higher than that reported for the commercially available contrast agent, 
Magnevist at low magnetic fields.   
 
(iv) investigate the hypoxia-targeting ability of the synthesised structures/agents in vitro by 
assessing the retention of paramagnetic metal ions in cells under hypoxic and normoxic 
conditions 
The hypoxia-targeting ability of the liposomes was assessed in two cell lines: SH-
SY5Y human neuroblastoma and MCF-7 human breast adenocarcinoma, in normoxic 
and hypoxic conditions. Indistinct contrast difference was observed between the MR 
images of the normoxic and hypoxic cells in either cell-line. However, ICP-MS 
revealed a three and five-fold increase in the Gd concentration of the hypoxic cells 
relative to the normoxic cells in the SH-SY5Y and MCF-7 cell lines, respectively, 
confirming the hypoxia-targeting ability of these liposomal formulations.  
 
124 
 
 Directions for Future Research 9.2
In this thesis, 2-nitroimidazole amphiphiles and commercially available paramagnetic 
amphiphiles were incorporated into the bilayer membrane of phosphatidylcholine 
phospholipids to create hypoxia-specific paramagnetic liposomes. By extending this principle 
to also incorporate hypoxia-activated prodrugs, such as AQ4N (1,4-bis([2-
(dimethylamino)ethyl]amino)-5,8-hydroxy-anthracene-9,10-dione bis-N-oxide), into the 
liposomes (either in the bilayer membrane or in the central region of the liposome), it may be 
possible to develop hypoxia-specific theranostic liposomes in the future [229, 230], which 
would see the combination of diagnostic and therapeutic capabilities in a single agent.  
A limitation of the hypoxia-specific paramagnetic agents that were developed in this 
thesis was the inability to observe a contrast difference between the hypoxic and normoxic 
samples using MRI. To ameliorate the MRI applications of such hypoxia-specific 
paramagnetic agents at high magnetic field strengths, it is imperative that a higher proportion 
of Gd amphiphilic chelates be incorporated within the liposomal bilayer membranes so that 
cellular uptake experiments can be performed with a higher Gd concentration. However, 
incorporating >33 mol% of the commercially available Gd-DTPA-BSA amphiphile within 
phospholipids is known to reduce the relaxivity of the liposomes [231]. Also, with a neutral 
head group in the Gd-DTPA-BSA amphiphile, higher concentrations can potentially make the 
liposomes unstable. Therefore, it might be better to impart hypoxia specificity to liposomes 
composed solely of paramagnetic amphiphiles with charged (usually anionic) head groups 
(i.e., without any phospholipids or cholesterol), as reported before [128, 232, 233]. However, 
considering the well-documented safety concerns on linear Gd chelates [122, 234], 
amphiphiles of the more stable macrocyclic paramagnetic chelates should replace the linear 
paramagnetic chelates.  
To further increase the potential of MRI applications, the relaxivity of the hypoxia-
specific paramagnetic liposomes will also need to be improved, especially at high magnetic 
field strengths. Note the relaxivity of all contrast agents diminish at high fields [235, 236]. 
However, by designing compounds with fast water exchange (i.e., exchange between the 
water molecule coordinated to the Gd ion with the bulk water) and optimum reorientational 
correlation time (which is dependent on the size of the molecules), it is possible to obtain 
liposomes with better relaxivities than the ones formulated in this present study. For example, 
compared to the saturated lipids used in the present study, unsaturated (e.g. oleyl/linoleyl) or 
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branched (e.g. phytanyl) lipid chains are known to increase the permeability of the bilayer 
membrane, leading to faster water exchange rate (through the bilayer membrane) and higher 
relaxivities [128, 237]. As a preliminary investigation to observe the change in relaxivity, 
another set of liposomes was developed replacing the saturated lipid, DPPC with the 
unsaturated lipid, 1,2-dioleoyl-sn-hlycero-3-phosphocholine (DOPC). The relaxivity (i.e., r1) 
at high field increased from 2.25 mM
-1
s
-1
 (using DPPC) to 3.31 mM
-1
s
-1
 (using DOPC). Note, 
however, that increased leakage due to high permeability of the bilayer membrane can also 
impede the drug-delivery properties of the liposomes. Therefore, a balance will need to be 
investigated between the diagnostic and therapeutic abilities in pursuit of the development of 
the next generation hypoxia-specific theranostic liposomes.  
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